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INDEX OF THE CHANGES
1. Provided all figures as separate files in .tif format with resolution of 600 dpi.
2. Added scale bar in all photomicrographs.
3. Western blot analysis of VCAM-1 expression in brain capillary lysates is replaced by Western blot 
analysis and ELISA of VACM-1 expression in kidney capillaries in supplementary figure 8.
4. Protocol for isolation of capillaries from kidney tissue is provided in the supplementary 
methods.
5. Details of VACM-1 ELISA kit and VCAM-1 antibody are added in the Methods section.
6. All changes in response to the reviewers’ comments are made in the manuscript (details are 
provided in ‘ITEMIZED RESPONSES’ sheet).
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We thank the editors and reviewers for their careful and helpful comments. We revised the 
manuscript as suggested.  Below are point-by-point responses.
Specific Comments Resulting from the Editorial Conference:
The manuscript was overall adequately revised. However, there remain some issues to be 
addressed. Please check the comments by the reviewers carefully and revise your manuscript.  
We will be glad to publish your MS afterwards.
Please make sure to upload a graphical abstract of your paper. Guidelines for content and a 
design template for this required graphical abstract are attached with this email. The Graphical 
Abstracts will be published as provided and will not be included with the proof.
Reviewer(s)' Comments to Author:
Reviewer: 1
Comments to the Author
There are a few minor issues that should be addressed.
1. Page 2 (Abstract): The first sentence of the abstract makes no sense to me. Please revise. Also, 
“whilst also reducING renal accumulation” (line 30).
Answer: The first sentence of the abstract was altered to read: “In type-2 diabetes, the oxygen-
carrying capacity of red blood cells (RBCs) and the integrity and stability of the blood capillaries 
decline causing tissue hypoxia and end organ malfunction.”
2. Page 5, line 15: “The upregulation of formation of epoxyeicosatrienoic acids (EETs) in 
endothelial cells (EC)”.
Answer: We made the suggested change
3. Page 6, line 8: “or stroke (S) also had elevated RBC…”.
Answer: We made the suggested change.
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4. Page 6, line 13: “…and C groups tag heart failure or cancer…”. I do not know what you mean 
by “tag” here.
Answer: We replaced “tag” by “indicate”.
5. Page 9, line 30: “Something cannot be “non-significantly higher”. You set a critical value of P 
to make a decision about rejecting or not rejecting the null hypothesis. You cannot have it both 
ways. I suggest something like, “…and tended to be higher in age-matched diabetic UCD rats (P 
= ??)”.
Answer: We replaced “non-significantly higher” by “tended to be higher in age-matched 
diabetic UCD rats (P = 0.27)”.”
6. Page 11, line 42: The word “arginase” is not a proper noun.
Answer: We replaced “Arginase” by “arginase”
7. Page 12, lines 1-6: “Impairment of tissue oxygen-sensing found in diabetic HIP rats was 
mirrored in control rats intravenously infused with amylin-coated RBCs and in diabetic UCD 
rats intravenously infused with human amylin.” This sentence does not convey your intended 
meaning. If rats are to be intravenously infused you would somehow have to stuff them into a 
syringe.
Answer: We rephrased the statement to read “Impairment of tissue oxygen-sensing found in 
diabetic HIP rats was mirrored in control rats that were given amylin-coated RBCs intravenously 
and in diabetic UCD rats that were given human amylin intravenously.”
8. Page 14, Lines 21-22: Please give the concentration of APAU in the drinking water. The 
stated “1 ml drug/L” is meaningless.
Answer:  APAU was formulated in polypropylene glycol at a concentration of 10 mg/mL with 30 
minutes sonication. The APAU aliquot was added to the drinking water at a final content of 1%.  
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Reviewer: 2
Comments to the Author
The authors have addressed most questions raised by the referees. However, there is still a few 
issues that should be addressed. 
First, in the Result section, you should clearly state brain tissue was sampled for western blot 
analysis shown in Supplementary Figure 7. 
Answer: In the meantime, we performed the VCAM-1 expression experiment on kidney 
capillary lysates and these data are now replacing the data on brain capillary lysates in 
Supplementary figure 8. 
Second, if VCAM-1 expression is up-regulated at the protein level, what is the ligand on RBC? 
The referee wonders that the putative molecule is integrin to play a key role in firm adhesion as 
you evaluated in Figure 5A. Please mention whatever is a candidate ligand on RBC in the 
Discussion section. 
Answer: The following sentence was added in the Discussion section “Future studies need to 
identify the ligand pairs for the amylin-mediated adhesive interaction between vascular ECs and 
RBCs. Candidate ligand pairs may include the VCAM-1-α4β1-integrin pair of proteins that 
appears to be involved in sickle cell disease40.” A relevant reference paper was added in the 
bibliography list: White J, Lancelot M, Sarnaik S, et al. Increased erythrocyte adhesion to 
VCAM-1 during pulsatile flow: Application of a microfluidic flow adhesion bioassay. Clin. 
Hemorheol. Microcirc. 2015;60:201-13  
Third, no asterisks in Figure 5A. Is there a significant difference between any pairs?
Answer: There is no difference between groups by one-way ANOVA. We revised the text 
describing the findings in Fig 5a to read:  The adhesion of RBCs to cultured vascular endothelial 
cells (ECs) under flow condition tended to be greater for HIP rat RBCs than RBCs from UCD 
rats (P = 0.17) and from WT rats (P = 0.17) (Figure 5a).
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Running headline: Biomarkers in diabetic microvascular dysfunction
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Abstract
In type-2 diabetes, the oxygen-carrying capacity of red blood cells (RBCs) and the integrity and stability 
of the blood capillaries decline causing tissue hypoxia and end organ malfunction. Correcting 
hyperglycemia is not entirely effective at reestablishing normal cellular metabolism and function. 
Identification of pathological changes occurring before the development of overt hyperglycemia may lead 
to novel therapeutic targets for reducing the risk of microvascular dysfunction.  Here we showed that the 
RBC-capillary interaction is altered by prediabetic hypersecretion of amylin, an amyloid-forming 
hormone co-synthesized with insulin, and is reversed by endothelial cell-secreted epoxyeicosatrienoic 
acids (EETs). In humans, we found amylin deposition in RBCs in association with type-2 diabetes, heart 
failure, cancer and stroke. Amylin-coated RBCs have altered shape and reduced functional (non-glycated) 
hemoglobin. Amylin-coated RBCs administered intravenously in control rats upregulated erythropoietin 
(EPO) and renal arginase expression and activity. We also found that diabetic rats expressing amyloid-
forming human amylin in the pancreas (HIP rats) have increased tissue levels of hypoxia-inducible 
transcription factors (HIFs) compared to diabetic rats that express non-amyloid forming rat amylin (UCD 
rats). EPO upregulation correlated with lower hematocrit in HIP rats indicating pathologic erythropoiesis. 
In HIP rats, pharmacological upregulation of endogenous EETs protected the renal microvasculature 
against amylin deposition whilst also reducing renal accumulation of HIFs. Thus, prediabetes induces 
amylin dyshomeostasis and promotes amylin deposition in RBCs and the microvasculature, which alters 
the RBC-capillary interaction leading to activation of hypoxia signaling pathways and pathologic 
erythropoiesis. Amylin dyshomeostasis could be a therapeutic target for ameliorating diabetic vascular 
complications.
Key words: Type-2-diabetes, Amylin, Microvascular Disease, Hypoxia, Erythropoiesis.
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Translational statement
Amylin accumulation in RBCs induces hypoxic-ischemic tissue injury. Detection of amylin accumulation 
in human RBCs, in combination with current American Heart Association guidelines to define 
cardiovascular risk, could result in better risk stratification for microvascular complications, improve the 
ability to predict progression of diabetic microvascular complications by taking a precision medicine 
approach, and better rationalize therapeutic strategies and response to treatment. 
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Introduction
Oxygen is essential for cell function and cell survival1. RBCs deliver oxygen to cells and tissues via 
mechanisms that involve the passage of RBCs through capillaries. This process is enabled by the 
viscoelastic properties of the RBCs, which allow them to be deformed within capillaries2. In type-2 
diabetes, the oxygen-carrying capacity of RBCs and the integrity and stability of the capillaries decline, 
exacerbating the risk of tissue hypoxia and end organ malfunction3-7. The underlying mechanisms are 
complex and incompletely understood.
Physiological responses to low oxygen levels are primarily driven by the stabilization of the α subunits of 
the hypoxia-inducible transcription factors HIF-1 and 21,8,9. HIF-2 regulates the hypoxia response by 
elevating the renal expression of EPO, a hormone that signals an increased demand for RBCs from the 
bone marrow, which then increases the production of RBCs8. Stabilization of HIF-2α also induces 
arginase expression9 in vascular endothelial cells. Because arginase has the same substrate (L-arginine) 
as nitric oxide (NO) synthase9, increased arginase production/ activation may reduce NO availability. 
Depleted NO production impairs relaxation of the blood vessels and affects microvascular 
autoregulation1,8,9. Thus, increased EPO coupled with arginase-NO dysregulation constitutes one of the 
multiple10 molecular derangements linking systemic hypoxia with microvascular dysfunction. 
Metabolic derangements that occur before the development of overt hyperglycemia may induce 
microvascular dysfunction11. In prediabetes, pancreatic β-cells compensate for insulin resistance by 
increasing the secretion of insulin (hyperinsulinemia)12. Amylin (also known as islet amyloid polypeptide; 
IAPP), is a 37-amino acid peptide synthesized and co-secreted with insulin in response to physiological 
stimuli13-15. It is normally soluble, crosses the blood brain barrier and binds to neurons in the feeding 
centers participating in the regulation of gastric fluxes16. Amylin from humans and a few other species, 
including cats, dogs and monkeys, but not rodents, has an increased propensity to aggregate, forming 
amyloid17 (i.e., amylin dyshomeostasis). This triggers β-cell apoptosis by mechanisms involving 
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incorporation of aggregated amylin into cellular membranes18-20. We21-26 and others27-31 have shown the 
presence of amylin deposition in failing hearts21-23 and kidneys27 of patients with type-2 diabetes and in 
brains28-31 of humans with dementia32. We also showed that rats that develop type-2 diabetes linked to 
amylin dyshomeostasis (i.e. the HIP rat model for type-2 diabetes33) develop heart dysfunction21,23 and 
neurological deficits25,34 sooner than age- and blood glucose-matched rats that develop type-2 diabetes in 
the absence of amylin dyshomeostasis (i.e. the UCD rat model for type-2 diabetes35). The upregulation of 
epoxyeicosatrienoic acids (EETs) in endothelial cells appeared to protect against cardiac amylin 
accumulation in HIP rats, which correlated with improved heart function22. Although we interpret these 
findings to support the hypothesis that reducing amylin dyshomeostasis may ameliorate diabetic vascular 
complications, the impact of elevated blood levels of amylin on blood cells and the microvasculature 
remains unknown. 
Here we tested the hypothesis that systemic amylin dyshomeostasis alters the interaction between RBCs 
and capillaries leading to hypoxic-ischemic tissue injury. To test this hypothesis, we measured the amylin 
levels in RBCs from humans with and without diabetes, and used transgenic rats, RBC transfusions and 
pharmacological tools for mechanistic studies.
Results 
Humans with type-2 diabetes have amylin deposition in RBCs. 
We assessed the relationship between HbA1c level (the common marker of hyperglycemia) and amylin 
concentration in RBC lysates from patients with type-2 diabetes or diseases that are commonly associated 
with insulin resistance, including heart failure, cancer and stroke. Western blot analysis of matched 
plasma, RBC lysate and white blood cell (WBC) lysate from a human with type-2 diabetes (the positive 
control for amylin dyshomeostasis) detected both monomeric amylin (Figure 1a) and amylin-positive 
higher molecular weight bands (Supplementary Figure 1). RBC lysates from individuals with a primary 
diagnosis of type-2 diabetes (T2D) (without heart failure, cancer or stroke) had higher amylin 
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6
concentration than those from healthy individuals (H) and patients with type-1 diabetes (T1D group; the 
negative control for amylin) (Figure 1b). Patients with a primary diagnosis of heart failure (HF), cancer 
(C), or stroke (S) also had elevated RBC amylin levels independent of type-2 diabetes as a secondary 
diagnosis (Figure 1b). Lighter colored symbols in the HF and C groups indicate heart failure or cancer 
without type-2 diabetes. RBC amylin and HbA1c levels were highly variable in all groups (Figure 1c-i), 
except in patients with HF and type-2 diabetes in whom higher HbA1c levels correlated with RBC amylin 
accumulation. There were non-significant inverse correlations between HbA1c and RBC amylin levels in 
the HF without diabetes (Figure 1f), cancer with diabetes (Figure 1g) and stroke (Figure 1i) groups. 
These results suggest that type-2 diabetes and diseases associated with insulin resistance such as heart 
failure, cancer and stroke promote amylin accumulation in RBCs in humans. 
Amylin deposition in RBCs results from hypersecretion of amyloid-forming human amylin.
The HIP rat is a unique animal model for late-life onset type-2 diabetes as it is characterized by pancreatic 
expression of the human (amyloid-forming) variant of amylin33, whereas other rodent models for type-2 
diabetes express only the native, non-amyloid forming amylin17. As in humans14, the development of type-
2 diabetes in HIP rats is associated with pancreatic amyloid33 (Supplementary Figure 2). We compared 
the amylin content in RBCs, WBCs, and plasma from diabetic HIP rats and non-diabetic WT littermates 
(Figure 2a). Amylin was concentrated in RBCs and the difference in amylin levels between WT and 
diabetic HIP rats was greater in RBCs than in plasma or WBCs (Figure 2a). 
Analysis of freshly packed RBCs by flow cytometry (Figure 2b) and amylin ELISA (Figure 2c) revealed 
a correlation between RBC amylin levels and different levels of non-fasted blood glucose (normal, ≤ 11 
mM, 6-8 months old; prediabetic, 11-14 mM on two consecutive measurements separated by >3 days, 10-
12 months old; and diabetic, >14 mM on two consecutive measurements, separated by >3 days; 14-16 
months old). 
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7
Confocal microscopy analysis of RBCs that were double-stained for amylin and hemoglobin showed 
amylin deposition on RBCs from HIP rats (Figure 2d). Amylin appeared to co-localize with glycophorin 
A (Figure 2e), a membrane protein that is specific to RBCs, suggesting amylin accumulation on the RBC 
membrane. The analysis of RBCs co-stained for amylin and glycophorin A using super-resolution imaging 
(STORM) showed the presence of amylin within the RBC membrane with some dense patches on the 
outer part of the cell membrane (Figure 2f). Electron microscopic examination of immunogold-labeled 
thin sections of epoxy resin-embedded RBCs indicated the presence of amylin within the cell membrane 
(Supplementary Figure 3; arrowhead pointing to amylin deposits).   
The results demonstrate that hypersecretion of the amyloid-forming human variant of amylin leads to 
amylin deposition within circulating RBCs.
Amylin-coated RBCs have lower deformability and functional (non-glycated) hemoglobin.  
Next, we investigated pathophysiological characteristics of RBCs from diabetic HIP rats and RBCs from 
diabetic rats without amylin dyshomeostasis (UCD rats) and non-diabetic WT rats, as they express only 
the non-amyloid forming rat amylin. Compared to RBCs from WT rats, RBCs from HIP rats contained 
less functional (non-glycated) hemoglobin (Figure 3a), whereas there was no difference between UCD 
and WT rats. RBCs of HIP, UCD and WT rats (~ 12 months old rats) had similar oxygen dissociation 
curves (Figure 3b) indicating that the affinity of hemoglobin for oxygen, the release of bound oxygen and 
the partial oxygen pressure for maintaining oxygen saturation are not significantly affected by amylin 
dyshomeostasis or hyperglycemia.
In flow cytometry experiments, the distribution of the forward scattering (FSC) signals by RBCs from 
WT rats (Figure 3c; orange) was bimodal, which reflects the biconcave disk shape of normal RBCs. In 
the case of amylin-coated RBCs from diabetic HIP rats, the FSC distribution was monomodal (Figure 3c; 
pink), indicating changes in RBC morphology towards a more spherical shape. The Pearson coefficient of 
dissymmetry (PCD), which indicates the departure from sphericity, suggested distinct morphological 
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changes in RBCs from HIP rats compared to WT and UCD rats (Figure 3c). Incubation of RBCs from 
WT rats with aggregated human amylin for 4 hours (as described in our previous studies26,36) replicated 
the morphological change observed in HIP rat RBCs (Supplementary Figure 4). Altered shape of RBCs 
from HIP and UCD rats did not affect the response to an osmotic resistance test, as the propensity for 
hemolysis in hypo-osmotic solutions was comparable for RBCs from all three rat groups (Figure 3d). 
These results show that amylin deposition in RBCs is associated with lower hemoglobin concentrations 
and reduced RBC deformability, independently of effects of chronic glucose levels. At an early stage of 
diabetes, the cumulative effects of amylin dyshomeostasis and hyperglycemia (as in HIP rats) or 
hyperglycemia alone (as in UCD rats) do not appear to induce significant changes in hemolysis and oxygen 
dissociation.
The microvasculature is disrupted in kidneys of rats with amylin dyshomeostasis. 
Next we investigated the structural integrity of the capillary network and the stability of the capillary beds 
in kidneys from age- and blood glucose-matched HIP and UCD rats. We used immunohistochemistry with 
antibodies against amylin (brown) and collagen IV (Col IV; green), a component of the basement 
membrane, to anatomically localize amylin deposition with respect to the vasculature. In HIP rat kidneys, 
there were patches of amylin deposits in arterioles, interstitial tissue between the tubules (Figure 3e) and 
glomeruli (Figure 3f). Vascular amylin deposition correlated with accumulation of macrophages, as 
indicated by co-staining for amylin and the ionized calcium-binding adapter molecule 1 (IBA1), a marker 
of macrophage activation (Figure 3g). There were macrophages in areas of amylin deposition, which may 
indicate a potential role for these cells in the clearance of vascular amylin deposition. Staining with ED1 
(Figure 3h), an antibody against the cluster of differentiation (CD) 68 protein (that is highly expressed by 
circulating macrophages), supports the increased activity of macrophages in areas of vascular amylin 
deposition. In contrast, vascular amylin deposits and macrophage infiltration were not found in kidneys 
from diabetic UCD rats.
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9
These data suggest that amylin dyshomeostasis injures the capillaries, which may be associated with 
systemic inflammatory responses leading to macrophage infiltration that may exacerbate ischemic 
vascular injury in HIP rats.
Amylin dyshomeostasis activates renal hypoxia signaling pathways.
The kidney is a critical component of a regulatory feedback loop that controls the hematocrit via EPO 
production8. Both HIP and UCD rats had renal dysfunction, as indicated by polyuria and albuminuria 
(Supplementary Figures 5a and 5b). Creatinine clearance was elevated in diabetic HIP rats compared with 
WT littermates and diabetic UCD rats (Supplementary Figure 5c). The plasma level of EPO, the hormone 
that signals an increased demand for RBCs to the bone marrow, was higher in diabetic HIP rats than in 
WT littermates (Figure 4a) and tended to be higher in age-matched diabetic UCD rats vs. WT rats (P = 
0.27). The reticulocyte count was also higher in HIP than in WT rats (Figure 4b). Despite elevated plasma 
EPO levels, the average hematocrit was not different in HIP rats compared with WT littermates, but was 
lower in HIP compared to UCD rats (Figure 4c). The spleen, a major blood reservoir, had lower weight in 
diabetic HIP rats compared to age-matched WT rats (Supplementary Figure 6). Compared with diabetic 
UCD rats and healthy WT rats, diabetic HIP rats had elevated levels of HIF-1α and HIF-2α in whole 
kidney tissue homogenates (Figure 4d and 4e). Consistent with elevated HIF-2α, HIP rat kidneys also had 
upregulated arginase-1 and 2 proteins (Figure 4f and 4g) and greater arginase activity (Figure 4h). 
Increased stabilization of HIF α units in HIP rat kidney tissue correlated with a trend towards 
downregulation of the von Hippel-Lindau (vHL) tumor suppressor protein (Supplementary Figure 7) 
suggesting impaired degradation of HIF α units. 
These results suggest that activation of hypoxia signaling in kidneys and downstream upregulation of EPO 
are associated with pathologic erythropoiesis and amylin deposition in RBCs.
Blocking of adhesion proteins in endothelium reverses amylin dyshomeostasis and HIF activation.
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The adhesion of RBCs to cultured vascular endothelial cells (ECs) under flow condition tended to be 
greater for HIP rat RBCs than RBCs from UCD rats (P = 0.17) and from WT rats (P = 0.17) (Figure 5a). 
Greater adhesion of RBCs from HIP rats to ECs was found in experiments without flow condition (Figure 
5b) in an adhesion test in which RBCs from WT rats that were incubated with 50 μM synthetic human 
amylin for 4 hours is shown in Figure 5c. Analysis of kidney capillary lysates by Western blot (A) and 
ELISA (B) showed a trend towards upregulation of the expression of vascular cell adhesion molecule 1 
(VCAM-1) in HIP rats (Supplementary Figure 8). Taken together, these results suggest that the cell 
membrane adhesion proteins may play a role in amylin accumulation at the RBC-capillary interface. To 
test this hypothesis, we used EETs, which are primarily expressed by vascular ECs37 and RBCs38 and are 
known to downregulate the expression of VCAM-1 in endothelium39. We found that ex vivo incubation 
with (±)14(15)-EET reduced the adhesion of HIP rat RBCs to cultured endothelial cells (Figure 5d). 
Upregulation of EETs by treatment with an inhibitor of soluble epoxide hydrolase, the enzyme that 
degrades endogenous EETs37, was associated with lower amylin deposition in renal microvasculature (the 
HIP-T group; Figure 5e). The treatment lowered renal accumulation of HIF-2α (Figure 5f) and HIF-1α 
(Figure 5g) and had variable effects on arginase expression and arginase activation (Supplementary Fig 
9) in HIP rat kidneys. 
Taken together, these results indicate that 1) reduced capillary RBC flux owing to amylin deposition on 
RBCs and the capillary wall likely contributes to tissue hypoxia in HIP rats and 2) EETs reduce this effect 
by downregulation of adhesion proteins in the vascular endothelium. 
Transfused amylin-coated RBCs upregulate EPO through HIF-2α activation in kidneys.
RBCs act as both oxygen carriers and mediators of oxygen sensing and signaling pathways within ECs8,9. 
To determine whether amylin deposition on RBCs activates hypoxia signaling pathways in tissues, 
amylin-coated RBCs from HIP rats were administered to WT rats. Rats were given 300 μl freshly packed 
RBCs/day for seven days. WT rats given similar volumes of RBCs from diabetic UCD rats were used as 
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positive controls for the possible effects of hyperglycemia on RBC function, whereas WT rats receiving 
RBCs from WT rats served as negative controls. Plasma levels of EPO were elevated in WT rats receiving 
amylin-coated RBCs from HIP rats compared to WT rats that received either RBCs from diabetic UCD 
rats or WT rats (Figure 6a). Kidneys of WT rats receiving HIP rat RBCs had increased stabilization of 
HIF-1α (Figure 6b) but no difference in HIF-2α levels (Figure 6c), compared with rats in the two control 
groups. 
To examine further a possible ‘amylin stress” on oxygen-sensing pathways, aggregated human amylin 
(hA) (0.08 μg/g body weight) was intravenously administered to diabetic UCD rats, daily, for one week. 
Intravenous infusion of aggregated human amylin in UCD rats led to amylin deposition on RBCs (Figure 
6d). This acute “amylin stress” provoked an increase in plasma EPO level (Figure 6e; the “after hA inj” 
rat group) and no difference in renal HIF-2α and HIF-1α levels in whole kidney tissue homogenate (Figure 
6f). Arginase 1 protein levels were elevated in kidney tissue homogenates from amylin-infused UCD rats, 
whereas there was no significant change of arginase 2 protein expression (Figure 6g). 
These data indicate elevated EPO and accumulation of HIFs in kidneys as a direct response to circulating 
amylin-coated RBCs (Figure 6h).
Discussion
We found that hypersecretion of human amylin is associated with amylin deposition in the 
microvasculature and RBCs leading to impaired RBC-capillary interaction and activation of hypoxia 
signaling pathways. Impairment of tissue oxygen-sensing found in diabetic HIP rats was mirrored in 
control rats that were given amylin-coated RBCs intravenously and in diabetic UCD rats that were given 
human amylin intravenously. These results indicate that amylin-coated RBCs are a trigger of hypoxia 
signaling pathways. These deleterious effects result in part from a reduced flux of amylin-coated RBCs 
through the capillaries that may involve adhesion proteins. Blocking the expression of adhesion proteins 
in the vascular endothelium by upregulation of EETs reduces amylin dyhomeostasis and HIF activation. 
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Future studies need to identify the ligand pairs for the amylin-mediated adhesive interaction between 
vascular ECs and RBCs. Candidate ligand pairs may include the VCAM-1-α4β1-integrin pair of proteins 
that appears to be involved in sickle cell disease40.   
This link between prediabetes-induced systemic amylin dyshomeostasis and tissue hypoxia has broad 
implications for health care because: 1) accumulating evidence demonstrates the presence of amylin 
deposition in vital organs21-31 and RBCs (as shown by the present human data) that may provide a 
therapeutic target reducing vascular injury prior the development of overt diabetes, 2) the public health 
impact of type-2 diabetes; and 3) the lack of drugs that counter amylin dyshomeostasis. 
Glycated hemoglobin has a higher affinity for oxygen than adult hemoglobin A (functional hemoglobin), 
and can disrupt the supply of oxygen to tissues41. Indeed, RBCs from hyperglycemic UCD rats have 
decreased deformability and functional hemoglobin compared with WT rats. RBC deformability and 
hemoglobin levels are even lower in HIP rats, which may explain, in part, the higher hypoxic response in 
control WT rats receiving RBCs from HIP rats compared to control rats receiving similar volumes of 
RBCs from UCD rats. 
Elevated EPO and microvascular dysfunction identify diabetic patients with increased risk of death42-44. 
In diabetic HIP rats, elevated plasma EPO does not correlate with an increase in hematocrit. HIP rat 
kidneys have amylin deposits in the microvasculature that co-localized with macrophage activation. Taken 
together, the results suggest that systemic amylin dyshomeostasis may upregulate eryptosis via 
macrophage activation. The results also indicate that amylin dyshomeostasis injures capillaries and is 
associated with inflammatory responses exacerbating ischemic vascular injury.
There are inherent limitations to our study of the interaction between pancreatic amylin secretion and 
RBCs. In the human study, we were not able to control for the potential effects of glucose, steroids, anti-
diabetic drugs or specific forms of anesthesia given to individual patients, which can affect pancreatic 
function including amylin and insulin secretion. 
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In conclusion, systemic amylin dyshomeostasis promotes amylin deposition in RBCs and the 
microvasculature associated with pathologic erythropoiesis, macrophage activation and macrophage 
accumulation in blood vessels. Future studies should determine whether the RBC amylin levels affect the 
course of microvascular complications.
Methods
Detailed Methods are included in Supplementary Materials.
Human studies
This research employed de-identified blood specimens matched with medical record data obtained from 
the biobank of the Center for Clinical and Translational Science at University of Kentucky. Sample 
collection and storage were approved by the Institutional Review Board. We assessed the relationship 
between HbA1c level and amylin concentration in RBC lysates from individuals with primary diagnosis 
of type-2 diabetes or diseases that are commonly associated with insulin resistance, including heart failure, 
cancer and stroke. RBC specimens were divided into groups based on the primary diagnosis of type-2 
diabetes, heart failure, cancer or stroke. Most humans in the heart failure and cancer groups had type-2 
diabetes as a second diagnosis. The negative control for amylin was RBC lysates from patients with over 
15 years of type-1 diabetes (and, therefore, depleted β-cell mass) who were otherwise healthy. The healthy 
control group included individuals without diabetes, heart failure, stroke or cancer. Exclusion criteria were 
based on conditions that may affect the pancreatic secretion of amylin such as transplant recipients (less 
than 6 months after the transplant), patients with liver disease, patients with HIV and pregnant or lactating 
women. Table 1 summarizes the diabetes status, co-morbidities, age, sex and body mass index (BMI) of 
the patients who provided the blood used in these analyses.
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Experimental Animals
All animal experiments conform to the NIH guide for the care and use of laboratory animals and were 
approved by the Institutional Animal Care and Use Committee at University of Kentucky. We compared 
rats that develop type-2 diabetes linked to expression of human amylin in the pancreas (HIP rats; n=65), 
with rats that develop type-2 diabetes in the absence of amyloid, as they express the non-amyloidogenic 
rat amylin (UCD rats; n=40) and control, non-diabetic rats (WT rats; n=53). 
Treatment
We performed a retrospective analysis of kidney tissue from a prior study22 in which HIP rats were treated 
for 10 weeks with a soluble epoxide inhibitor APAU (UC1153) added to their drinking water in order to 
upregulate the endogenous EET levels. APAU was formulated in polypropylene glycol at a concentration 
of 10 mg/mL with 30 minutes sonication. The APAU aliquot was added to the drinking water at a final 
content of 1%.  
Renal function analysis
Urine and blood were collected from rats in metabolic cages. Creatinine concentration in plasma and urine 
was measured using the kinetic Jaffé method45. Creatinine clearance (Ccr) was calculated using the 
formula: Ccr (ml/min) = (urine creatinine/plasma creatinine) × urine flow rate. Urinary albumin was 
measured by ELISA. 
Tissue extraction and RBC isolation
For measurements of hypoxia markers (hypoxia-inducible transcription factors 1α, HIF1-α, and 2α, HIF2-
α, arginase 1, arginase 2 and von Hippel-Lindau factor, vHL) and arginase activity, kidney tissue was 
extracted in PBS with protease and phosphatase inhibitors, followed by three consecutive cycles of 
freezing to -80°C and thawing. For other biochemical assays, tissues were extracted in homogenization 
buffer containing Triton X-100, SDS and protease and phosphatase inhibitors. 
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RBCs were isolated immediately after blood collection by centrifugation at 1,000g. For some experiments, 
RBCs were lysed in lysis buffer containing 10% NP-40. 
RBC transfusion
Isolated RBCs were combined with storage solution (150 mM HCl, 45 mM dextrose, 45.5 mM mannitol, 
and 2.2 mM adenine) in a 3:1 v/v ratio, transferred to sterile tubes and stored at 4°C in the dark before 
injection. Rats received 300 µL of pre-warmed (at 37º C) RBC solution once daily for 7 days via tail vein 
injection.
Hematocrit and hemoglobin measurements
Hematocrit was measured with an i-STAT analyzer using i-STAT CG8+ cartridges according to the 
manufacturer’s protocol. Hemoglobin content was calculated from the optical density at 405 nm.
Assessment of RBC shape and amylin deposition on RBCs by flow cytometry
RBCs were incubated with an anti-amylin antibody followed by incubation with an anti-rabbit Alexa 
Fluor® 488 secondary antibody. Flow cytometry was performed with a Becton Dickinson LSRII 
instrument. To assess cell shape, RBCs were first gated on a forward scatter (FSC)/side scatter (SSC) plot. 
The region 1 (R1) events were visualized using a FSC-A/FSC-H dot plot. For detecting amylin deposited 
on RBCs, cells were first gated on a forward scatter (FSC)/side scatter (SSC) plot. RBCs were further 
gated to determine the amylin signal (Alexa 488), using negative control (no antibody) and positive control 
(RBCs incubated with 50 μM of synthetic amylin peptide) to set the upper and lower boundaries. 
Immunofluorescence
Isolated RBCs were incubated with primary antibodies against human amylin and glycophorin A, 
followed by incubation secondary antibodies, and imaged with a Nikon A1R confocal microscope. For 
hemoglobin staining, blood smears on glass slide were fixed and incubated with primary antibodies against 
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hemoglobin and human amylin. Smears were then incubated with secondary antibodies, mounted in 
mounting media and imaged.
Biochemical assays
ELISA for human amylin, erythropoietin, HIF1-α, HIF2-α, arginase 1, arginase 2 and vHL were 
performed according to the manufacturer’s protocols. Arginase activity was measured in kidney 
homogenates using a colorimetric assay. Western blots were performed on plasma, WBC lysates, RBC 
lysates from humans and using a primary antibody against amylin and on kidney capillary lysates from 
rats using a primary antibody against VCAM-1 (1:1000, ab134047, Abcam). 
Immunohistochemistry
Immunohistochemical staining was performed on rat kidney slices using antibodies against amylin, 
collagen IV, IBA-1, and ED1). The staining area for amylin was analyzed in ImageJ. 
Statistical analysis
Statistical differences between groups were determined using Student’s t-test, one-way ANOVA or two-
way ANOVA, as appropriate. Multiple comparison and P values were calculated by Bonferroni correction 
for human data. P value for each regression analysis was calculated by the Spearman correlation test.
Disclosures: The authors have declared that no conflict of interest exists.
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Supplementary Materials
Supplementary Figure Legends
Supplementary Figure S1. Left) Representative western blot analysis of high molecular weight amylin 
oligomers in plasma, RBC lysate and white blood cell (WBC) lysate from an individual with type-2 
diabetes. (Right) The Ponceau S staining of the blot show in Left panel. 
Supplementary Figure S2. Representative images of Thioflavin S (green) and amylin (red) staining in 
the pancreas from a diabetic HIP and a control WT rat (n=3/group). Scale bar, 30 µm.
Supplementary Figure S3. Representative TEM images showing RBCs from HIP and WT rats, stained 
with human amylin primary antibody and gold (10nm) labelled secondary antibody. (Scale bar 1µm)
Supplementary Figure S4. PCD for WT rat RBCs and WT rat RBCs incubated ex vivo with oligomerized 
human amylin (n=5 preparations/group).
Supplementary Figure S5. Volume of urine excretion (A), albuminuria (B) and creatinine clearance rate 
(C) in 16 months old WT, diabetic UCD and diabetic HIP rats (n=6 rats/group). **P <0.01; ***P <0.001 
by One-way ANOVA.
Supplementary Figure S6. Gross spleen weights of 16 months old WT rats and diabetic HIP rats (n=10 
spleens/group). Data are means + SEM. *P <0.05
Supplementary Figure S7. Levels of von Hippel-Lindau (vHL) protein in the renal tissues from 16 
months old WT rats and diabetic HIP rats (n=5 rats/group). Data are means + SEM. 
Supplementary Figure S8. Western blot and ELISA analyses for VCAM-1 expression in kidney 
capillaries lysates of WT and HIP rats (n= 3 rats/group).
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Supplementary Figure S9. Reduced amylin deposition in kidneys correlated with partially reduced 
imbalance of arginase expression and arginase activation in HIP rat kidney tissues. (n=4 rats/group). Data 
are means + SEM. *P <0.05
Supplementary Methods
Supplementary References
Supplementary information is available at www.kidney-international.org
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Figure Legends
Fig. 1. Amylin-coated RBCs in human pathology. (a) Representative Western blots showing the amylin 
monomer in matched plasma, RBC and white blood cell (WBC) lysates from an individual with type-2 
diabetes. Recombinant human amylin served as control. (b) Whisker box plots comparing the 
concentration of amylin, measured by ELISA, in RBCs from healthy individuals (h; dark green; n=66) 
versus individuals with various diseases or combination thereof, including type-2 diabetes (T2D; blue; 
n=69), heart failure (HF) with diabetes (HF-T2D; dark red; n=49) and without diabetes (HF w/o T2D; 
light red; n=59), cancer with diabetes (C-T2D; black; n=33) and without diabetes (C; gray; n=58), and 
stroke (S; yellow; n=13). RBC lysates from patients with type 1 diabetes (T1D; black; n=5) are the 
negative control for amylin. Statistical significance of the differences in amylin level was assessed using 
One-way ANOVA with the Bonferroni post-test for comparing all pairs of columns. *P<0.05, **P <0.01, 
***P <0.001, ****P <0.0001. The correlation between RBC amylin and HbA1c in groups of healthy (c) 
and diseased individuals (d-i) described in (b). Out-of axis amylin-HbA1c levels: 25.2-5.8 and 12.2-4.6 in 
(d); 16.3-5.5 in (f) and 10.7-5.3 and 13.1-5.1 in (i), respectively. The Spearman nonparametric correlation 
analysis was performed in GraphPad and the values for the Spearman r and P are indicated on the plots. 
 
Fig. 2. Accumulation of amyloid-forming human amylin in RBCs from diabetic rats. (a) Amylin 
concentration, measured by ELISA, in matched plasma and lysates of WBCs and RBCs from HIP rats and 
WT littermates (n=4/group). (b) Representative flow cytometry graphs (upper) and mean intensity (lower) 
for amylin/Alexa Fluor 488 fluorescence in RBCs from healthy, prediabetic and diabetic HIP rats (n=5 
rats/group). (c) Amylin concentration in RBC lysates from 16 months old WT rats (n=7) and healthy 
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(n=6), prediabetic (n=15) and diabetic (n=16) HIP rats measured by ELISA. (d and e) Representative 
images of co-staining for amylin and hemoglobin (d) and amylin and glycophorin A (e) in RBCs from 
age-matched WT and diabetic HIP rats (n=3 rats/group). Scale bar, 10 µm (top row) and 5 µm (midle and 
bottom rows). (f) Representative STORM images showing RBCS from HIP and WT rats stained for human amylin 
(red) and Glycophorin A (green). (Scale bar 2µm). (n=3 for each rat group). *P <0.05; **P <0.01 by t-test (a) 
and One-way ANOVA (b and c).
 
Fig. 3. Pathophysiological changes induced by amyloid-forming amylin in RBCs. (a) Hemoglobin 
levels in RBCs from WT, HIP and UCD rats (n=11 rats/group). (b) Oxygen dissociation curve for RBCs 
from WT, HIP and UCD rats (n=5 rats/group). (c) Representative example of cell shape distribution of 
RBCs from WT (orange), UCD (blue) and HIP (pink) rats (n=6 rats/group) and the Pearson coefficient of 
dissymmetry (PCD) calculated from these data. (d) Percentage of RBC hemolysis in hypo-osmotic 
solutions. The NaCl concentration for 50% hemolysis of WT, HIP and UCD RBCs is indicated in the 
inset. (n=4 rats/group). (e and f) Representative images of co-staining for amylin and collagen IV (Col 
IV) in kidney tissue sections showing amylin deposition in arterioles and interstitial tissue (e) and in the 
glomerulus (f) in diabetic HIP rats but not in diabetic UCD rats (n=3 rats/group). (g) Representative 
images of co-staining for amylin and ionized calcium binding adaptor molecule 1 (IBA1) in kidney tissue 
sections from diabetic HIP and diabetic UCD rats (n=3 rats/group). (h) Representative images of staining 
for the cluster of differentiation 68 (CD68; ED1) in kidney tissue section from diabetic HIP and diabetic 
UCD rats (n=3 rats/group). (Scale bar 50µm) *P<0.05; **P<0.01 by One-way ANOVA with Tukey’s 
post-test (a and c). 
 
Fig. 4. Modulation of renal hypoxia markers by amylin dyshomeostasis. (a) EPO levels in plasma 
from 16 months WT rats (n=17), diabetic UCD rats (n=8) and diabetic HIP rats (n=17). (b) Percentage 
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number of reticulocytes over total numbers of RBCs in blood of WT, HIP and UCD rats (n=3 for each rat 
group). (c) Hematocrit levels in diabetic HIP and UCD rats and WT controls (n=6 rats/group). (d-h) 
Protein levels of HIF-1α (d), HIF-2α (e), arginase-1 (f) and arginase-2 (g) and arginase activity (h) 
measured by ELISA in renal tissues from 16 months old WT rats and diabetic UCD and HIP rats (n=10 
rats/group). *P <0.05; **P <0.01; ***P <0.001 by One-way ANOVA with Tukey’s post-test. 
 Fig. 5. Effect of increasing endogenous EETs on RBC-capillary coupling and renal hypoxia 
signaling. (a) Average numbers of RBCs adhered to cultured vascular endothelial cells when fixed 
hematocrit of RBCs flowed over cultured EC at constant rate for constant time of 20 minutes (n=3/ group). 
(b) Analysis of the adhesion of RBCs isolated from HIP rats and WT littermates to cultured vascular 
endothelial cells (n=8/group). (c) Adhesion of WT rat RBCs to cultured vascular endothelial cells 
with/without incubation with recombinant human amylin (50 μM) for 2 hours (n=5/group). (d) Attachment 
of RBCs from WT and diabetic HIP rats to vascular endothelial cells in the absence or in the presence of 
various amounts of EETs (n=8 rats/group). (e) Representative images of staining for amylin and Col IV 
in kidney sections from diabetic HIP rats (HIP-UT) and diabetic HIP rats with pharmacologically 
upregulated EETs (HIP-T). The scatterplot shows the percentage of the tissue area that is positive for 
amylin (n=3 rats/group). (f-g) Protein levels of HIF-2α (f) and HIF-1α (g) in whole kidney tissue 
homogenate from rats in the HIP-UT and HIP-T groups (n=4 rats/group). *P <0.05; **P <0.01; ***P 
<0.001 by t-test. 
 
Fig. 6. Altered oxygen sensing in kidneys following transfusion with amylin-loaded RBCs
(a) Plasma EPO levels in WT rats transfused with RBCs from i) WT rats (n=7); ii) diabetic UCD rats 
(n=7) and iii) diabetic HIP rats (n=7). (b and c) Protein levels of HIF-1α (b) and HIF-2α (c) in renal tissue 
homogenate from the rats described in (a). (d) Representative images of amylin and glycophorin A co-
Page 30 of 121
The International Society of Nephrology (http://www.isn-online.org/site/cms)
Kidney International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
27
staining (left panel) and of amylin and hemoglobin co-staining (right panel) in RBCs from UCD rats 
infused with aggregated human amylin (daily injection of 0.08 μg/g body weight for 7 days; n=3 
rats/group). (e) Plasma EPO levels in diabetic UCD rats (n=3) at baseline and at the end of the acute 
intravenous treatment with aggregated human amylin (hA). (f-g) Protein levels of HIF-2α and HIF-1α 
 (f) and arginase-1 and arginase-2 (g) in renal tissue homogenates from diabetic UCD rats injected with 
human amylin versus non-injected diabetic UCD control rats (n=3 rats/group). (h) Cartoon illustrating the 
proposed mechanism through which “human” hyperamylinemia exacerbates hypoxia signalingin diabetic 
rats with pancreatic expression of non-amyloid forming amylin rat amylin (UCD rats). *P <0.05; **P 
<0.01; ***P <0.001 by One-way ANOVA with Tukey’s post-test (a-c) or two-tailed t-test (e-g).
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Running headline: Biomarkers in diabetic microvascular dysfunction
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Abstract
In type-2 diabetes, the oxygen-carrying capacity of red blood cells (RBCs) and the integrity and stability 
of the blood capillaries decline causing tissue hypoxia and end organ malfunction. Correcting 
hyperglycemia is not entirely effective at reestablishing normal cellular metabolism and function. 
Identification of pathological changes occurring before the development of overt hyperglycemia may lead 
to novel therapeutic targets for reducing the risk of microvascular dysfunction.  Here we showed that the 
RBC-capillary interaction is altered by prediabetic hypersecretion of amylin, an amyloid-forming 
hormone co-synthesized with insulin, and is reversed by endothelial cell-secreted epoxyeicosatrienoic 
acids (EETs). In humans, we found amylin deposition in RBCs in association with type-2 diabetes, heart 
failure, cancer and stroke. Amylin-coated RBCs have altered shape and reduced functional (non-glycated) 
hemoglobin. Amylin-coated RBCs administered intravenously in control rats upregulated erythropoietin 
(EPO) and renal arginase expression and activity. We also found that diabetic rats expressing amyloid-
forming human amylin in the pancreas (HIP rats) have increased tissue levels of hypoxia-inducible 
transcription factors (HIFs) compared to diabetic rats that express non-amyloid forming rat amylin (UCD 
rats). EPO upregulation correlated with lower hematocrit in HIP rats indicating pathologic erythropoiesis. 
In HIP rats, pharmacological upregulation of endogenous EETs protected the renal microvasculature 
against amylin deposition whilst also reducing renal accumulation of HIFs. Thus, prediabetes induces 
amylin dyshomeostasis and promotes amylin deposition in RBCs and the microvasculature, which alters 
the RBC-capillary interaction leading to activation of hypoxia signaling pathways and pathologic 
erythropoiesis. Amylin dyshomeostasis could be a therapeutic target for ameliorating diabetic vascular 
complications.
Key words: Type-2-diabetes, Amylin, Microvascular Disease, Hypoxia, Erythropoiesis.
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Translational statement
Amylin accumulation in RBCs induces hypoxic-ischemic tissue injury. Detection of amylin accumulation 
in human RBCs, in combination with current American Heart Association guidelines to define 
cardiovascular risk, could result in better risk stratification for microvascular complications, improve the 
ability to predict progression of diabetic microvascular complications by taking a precision medicine 
approach, and better rationalize therapeutic strategies and response to treatment. 
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Introduction
Oxygen is essential for cell function and cell survival1. RBCs deliver oxygen to cells and tissues via 
mechanisms that involve the passage of RBCs through capillaries. This process is enabled by the 
viscoelastic properties of the RBCs, which allow them to be deformed within capillaries2. In type-2 
diabetes, the oxygen-carrying capacity of RBCs and the integrity and stability of the capillaries decline, 
exacerbating the risk of tissue hypoxia and end organ malfunction3-7. The underlying mechanisms are 
complex and incompletely understood.
Physiological responses to low oxygen levels are primarily driven by the stabilization of the α subunits of 
the hypoxia-inducible transcription factors HIF-1 and 21,8,9. HIF-2 regulates the hypoxia response by 
elevating the renal expression of EPO, a hormone that signals an increased demand for RBCs from the 
bone marrow, which then increases the production of RBCs8. Stabilization of HIF-2α also induces 
arginase expression9 in vascular endothelial cells. Because arginase has the same substrate (L-arginine) 
as nitric oxide (NO) synthase9, increased arginase production/ activation may reduce NO availability. 
Depleted NO production impairs relaxation of the blood vessels and affects microvascular 
autoregulation1,8,9. Thus, increased EPO coupled with arginase-NO dysregulation constitutes one of the 
multiple10 molecular derangements linking systemic hypoxia with microvascular dysfunction. 
Metabolic derangements that occur before the development of overt hyperglycemia may induce 
microvascular dysfunction11. In prediabetes, pancreatic β-cells compensate for insulin resistance by 
increasing the secretion of insulin (hyperinsulinemia)12. Amylin (also known as islet amyloid polypeptide; 
IAPP), is a 37-amino acid peptide synthesized and co-secreted with insulin in response to physiological 
stimuli13-15. It is normally soluble, crosses the blood brain barrier and binds to neurons in the feeding 
centers participating in the regulation of gastric fluxes16. Amylin from humans and a few other species, 
including cats, dogs and monkeys, but not rodents, has an increased propensity to aggregate, forming 
amyloid17 (i.e., amylin dyshomeostasis). This triggers β-cell apoptosis by mechanisms involving 
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incorporation of aggregated amylin into cellular membranes18-20. We21-26 and others27-31 have shown the 
presence of amylin deposition in failing hearts21-23 and kidneys27 of patients with type-2 diabetes and in 
brains28-31 of humans with dementia32. We also showed that rats that develop type-2 diabetes linked to 
amylin dyshomeostasis (i.e. the HIP rat model for type-2 diabetes33) develop heart dysfunction21,23 and 
neurological deficits25,34 sooner than age- and blood glucose-matched rats that develop type-2 diabetes in 
the absence of amylin dyshomeostasis (i.e. the UCD rat model for type-2 diabetes35). The upregulation of 
epoxyeicosatrienoic acids (EETs) in endothelial cells appeared to protect against cardiac amylin 
accumulation in HIP rats, which correlated with improved heart function22. Although we interpret these 
findings to support the hypothesis that reducing amylin dyshomeostasis may ameliorate diabetic vascular 
complications, the impact of elevated blood levels of amylin on blood cells and the microvasculature 
remains unknown. 
Here we tested the hypothesis that systemic amylin dyshomeostasis alters the interaction between RBCs 
and capillaries leading to hypoxic-ischemic tissue injury. To test this hypothesis, we measured the amylin 
levels in RBCs from humans with and without diabetes, and used transgenic rats, RBC transfusions and 
pharmacological tools for mechanistic studies.
Results 
Humans with type-2 diabetes have amylin deposition in RBCs. 
We assessed the relationship between HbA1c level (the common marker of hyperglycemia) and amylin 
concentration in RBC lysates from patients with type-2 diabetes or diseases that are commonly associated 
with insulin resistance, including heart failure, cancer and stroke. Western blot analysis of matched 
plasma, RBC lysate and white blood cell (WBC) lysate from a human with type-2 diabetes (the positive 
control for amylin dyshomeostasis) detected both monomeric amylin (Figure 1a) and amylin-positive 
higher molecular weight bands (Supplementary Figure 1). RBC lysates from individuals with a primary 
diagnosis of type-2 diabetes (T2D) (without heart failure, cancer or stroke) had higher amylin 
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concentration than those from healthy individuals (H) and patients with type-1 diabetes (T1D group; the 
negative control for amylin) (Figure 1b). Patients with a primary diagnosis of heart failure (HF), cancer 
(C), or stroke (S) also had elevated RBC amylin levels independent of type-2 diabetes as a secondary 
diagnosis (Figure 1b). Lighter colored symbols in the HF and C groups indicate heart failure or cancer 
without type-2 diabetes. RBC amylin and HbA1c levels were highly variable in all groups (Figure 1c-i), 
except in patients with HF and type-2 diabetes in whom higher HbA1c levels correlated with RBC amylin 
accumulation. There were non-significant inverse correlations between HbA1c and RBC amylin levels in 
the HF without diabetes (Figure 1f), cancer with diabetes (Figure 1g) and stroke (Figure 1i) groups. 
These results suggest that type-2 diabetes and diseases associated with insulin resistance such as heart 
failure, cancer and stroke promote amylin accumulation in RBCs in humans. 
Amylin deposition in RBCs results from hypersecretion of amyloid-forming human amylin.
The HIP rat is a unique animal model for late-life onset type-2 diabetes as it is characterized by pancreatic 
expression of the human (amyloid-forming) variant of amylin33, whereas other rodent models for type-2 
diabetes express only the native, non-amyloid forming amylin17. As in humans14, the development of type-
2 diabetes in HIP rats is associated with pancreatic amyloid33 (Supplementary Figure 2). We compared 
the amylin content in RBCs, WBCs, and plasma from diabetic HIP rats and non-diabetic WT littermates 
(Figure 2a). Amylin was concentrated in RBCs and the difference in amylin levels between WT and 
diabetic HIP rats was greater in RBCs than in plasma or WBCs (Figure 2a). 
Analysis of freshly packed RBCs by flow cytometry (Figure 2b) and amylin ELISA (Figure 2c) revealed 
a correlation between RBC amylin levels and different levels of non-fasted blood glucose (normal, ≤ 11 
mM, 6-8 months old; prediabetic, 11-14 mM on two consecutive measurements separated by >3 days, 10-
12 months old; and diabetic, >14 mM on two consecutive measurements, separated by >3 days; 14-16 
months old). 
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Confocal microscopy analysis of RBCs that were double-stained for amylin and hemoglobin showed 
amylin deposition on RBCs from HIP rats (Figure 2d). Amylin appeared to co-localize with glycophorin 
A (Figure 2e), a membrane protein that is specific to RBCs, suggesting amylin accumulation on the RBC 
membrane. The analysis of RBCs co-stained for amylin and glycophorin A using super-resolution imaging 
(STORM) showed the presence of amylin within the RBC membrane with some dense patches on the 
outer part of the cell membrane (Figure 2f). Electron microscopic examination of immunogold-labeled 
thin sections of epoxy resin-embedded RBCs indicated the presence of amylin within the cell membrane 
(Supplementary Figure 3; arrowhead pointing to amylin deposits).   
The results demonstrate that hypersecretion of the amyloid-forming human variant of amylin leads to 
amylin deposition within circulating RBCs.
Amylin-coated RBCs have lower deformability and functional (non-glycated) hemoglobin.  
Next, we investigated pathophysiological characteristics of RBCs from diabetic HIP rats and RBCs from 
diabetic rats without amylin dyshomeostasis (UCD rats) and non-diabetic WT rats, as they express only 
the non-amyloid forming rat amylin. Compared to RBCs from WT rats, RBCs from HIP rats contained 
less functional (non-glycated) hemoglobin (Figure 3a), whereas there was no difference between UCD 
and WT rats. RBCs of HIP, UCD and WT rats (~ 12 months old rats) had similar oxygen dissociation 
curves (Figure 3b) indicating that the affinity of hemoglobin for oxygen, the release of bound oxygen and 
the partial oxygen pressure for maintaining oxygen saturation are not significantly affected by amylin 
dyshomeostasis or hyperglycemia.
In flow cytometry experiments, the distribution of the forward scattering (FSC) signals by RBCs from 
WT rats (Figure 3c; orange) was bimodal, which reflects the biconcave disk shape of normal RBCs. In 
the case of amylin-coated RBCs from diabetic HIP rats, the FSC distribution was monomodal (Figure 3c; 
pink), indicating changes in RBC morphology towards a more spherical shape. The Pearson coefficient of 
dissymmetry (PCD), which indicates the departure from sphericity, suggested distinct morphological 
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8
changes in RBCs from HIP rats compared to WT and UCD rats (Figure 3c). Incubation of RBCs from 
WT rats with aggregated human amylin for 4 hours (as described in our previous studies26,36) replicated 
the morphological change observed in HIP rat RBCs (Supplementary Figure 4). Altered shape of RBCs 
from HIP and UCD rats did not affect the response to an osmotic resistance test, as the propensity for 
hemolysis in hypo-osmotic solutions was comparable for RBCs from all three rat groups (Figure 3d). 
These results show that amylin deposition in RBCs is associated with lower hemoglobin concentrations 
and reduced RBC deformability, independently of effects of chronic glucose levels. At an early stage of 
diabetes, the cumulative effects of amylin dyshomeostasis and hyperglycemia (as in HIP rats) or 
hyperglycemia alone (as in UCD rats) do not appear to induce significant changes in hemolysis and oxygen 
dissociation.
The microvasculature is disrupted in kidneys of rats with amylin dyshomeostasis. 
Next we investigated the structural integrity of the capillary network and the stability of the capillary beds 
in kidneys from age- and blood glucose-matched HIP and UCD rats. We used immunohistochemistry with 
antibodies against amylin (brown) and collagen IV (Col IV; green), a component of the basement 
membrane, to anatomically localize amylin deposition with respect to the vasculature. In HIP rat kidneys, 
there were patches of amylin deposits in arterioles, interstitial tissue between the tubules (Figure 3e) and 
glomeruli (Figure 3f). Vascular amylin deposition correlated with accumulation of macrophages, as 
indicated by co-staining for amylin and the ionized calcium-binding adapter molecule 1 (IBA1), a marker 
of macrophage activation (Figure 3g). There were macrophages in areas of amylin deposition, which may 
indicate a potential role for these cells in the clearance of vascular amylin deposition. Staining with ED1 
(Figure 3h), an antibody against the cluster of differentiation (CD) 68 protein (that is highly expressed by 
circulating macrophages), supports the increased activity of macrophages in areas of vascular amylin 
deposition. In contrast, vascular amylin deposits and macrophage infiltration were not found in kidneys 
from diabetic UCD rats.
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These data suggest that amylin dyshomeostasis injures the capillaries, which may be associated with 
systemic inflammatory responses leading to macrophage infiltration that may exacerbate ischemic 
vascular injury in HIP rats.
Amylin dyshomeostasis activates renal hypoxia signaling pathways.
The kidney is a critical component of a regulatory feedback loop that controls the hematocrit via EPO 
production8. Both HIP and UCD rats had renal dysfunction, as indicated by polyuria and albuminuria 
(Supplementary Figures 5a and 5b). Creatinine clearance was elevated in diabetic HIP rats compared with 
WT littermates and diabetic UCD rats (Supplementary Figure 5c). The plasma level of EPO, the hormone 
that signals an increased demand for RBCs to the bone marrow, was higher in diabetic HIP rats than in 
WT littermates (Figure 4a) and tended to be higher in age-matched diabetic UCD rats vs. WT rats (P = 
0.27). The reticulocyte count was also higher in HIP than in WT rats (Figure 4b). Despite elevated plasma 
EPO levels, the average hematocrit was not different in HIP rats compared with WT littermates, but was 
lower in HIP compared to UCD rats (Figure 4c). The spleen, a major blood reservoir, had lower weight in 
diabetic HIP rats compared to age-matched WT rats (Supplementary Figure 6). Compared with diabetic 
UCD rats and healthy WT rats, diabetic HIP rats had elevated levels of HIF-1α and HIF-2α in whole 
kidney tissue homogenates (Figure 4d and 4e). Consistent with elevated HIF-2α, HIP rat kidneys also had 
upregulated arginase-1 and 2 proteins (Figure 4f and 4g) and greater arginase activity (Figure 4h). 
Increased stabilization of HIF α units in HIP rat kidney tissue correlated with a trend towards 
downregulation of the von Hippel-Lindau (vHL) tumor suppressor protein (Supplementary Figure 7) 
suggesting impaired degradation of HIF α units. 
These results suggest that activation of hypoxia signaling in kidneys and downstream upregulation of EPO 
are associated with pathologic erythropoiesis and amylin deposition in RBCs.
Blocking of adhesion proteins in endothelium reverses amylin dyshomeostasis and HIF activation.
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The adhesion of RBCs to cultured vascular endothelial cells (ECs) under flow condition tended to be 
greater for HIP rat RBCs than RBCs from UCD rats (P = 0.17) and from WT rats (P = 0.17) (Figure 5a). 
Greater adhesion of RBCs from HIP rats to ECs was found in experiments without flow condition (Figure 
5b) in an adhesion test in which RBCs from WT rats that were incubated with 50 μM synthetic human 
amylin for 4 hours is shown in Figure 5c. Analysis of kidney capillary lysates by Western blot (A) and 
ELISA (B) showed a trend towards upregulation of the expression of vascular cell adhesion molecule 1 
(VCAM-1) in HIP rats (Supplementary Figure 8). Taken together, these results suggest that the cell 
membrane adhesion proteins may play a role in amylin accumulation at the RBC-capillary interface. To 
test this hypothesis, we used EETs, which are primarily expressed by vascular ECs37 and RBCs38 and are 
known to downregulate the expression of VCAM-1 in endothelium39. We found that ex vivo incubation 
with (±)14(15)-EET reduced the adhesion of HIP rat RBCs to cultured endothelial cells (Figure 5d). 
Upregulation of EETs by treatment with an inhibitor of soluble epoxide hydrolase, the enzyme that 
degrades endogenous EETs37, was associated with lower amylin deposition in renal microvasculature (the 
HIP-T group; Figure 5e). The treatment lowered renal accumulation of HIF-2α (Figure 5f) and HIF-1α 
(Figure 5g) and had variable effects on arginase expression and arginase activation (Supplementary Fig 
9) in HIP rat kidneys. 
Taken together, these results indicate that 1) reduced capillary RBC flux owing to amylin deposition on 
RBCs and the capillary wall likely contributes to tissue hypoxia in HIP rats and 2) EETs reduce this effect 
by downregulation of adhesion proteins in the vascular endothelium. 
Transfused amylin-coated RBCs upregulate EPO through HIF-2α activation in kidneys.
RBCs act as both oxygen carriers and mediators of oxygen sensing and signaling pathways within ECs8,9. 
To determine whether amylin deposition on RBCs activates hypoxia signaling pathways in tissues, 
amylin-coated RBCs from HIP rats were administered to WT rats. Rats were given 300 μl freshly packed 
RBCs/day for seven days. WT rats given similar volumes of RBCs from diabetic UCD rats were used as 
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positive controls for the possible effects of hyperglycemia on RBC function, whereas WT rats receiving 
RBCs from WT rats served as negative controls. Plasma levels of EPO were elevated in WT rats receiving 
amylin-coated RBCs from HIP rats compared to WT rats that received either RBCs from diabetic UCD 
rats or WT rats (Figure 6a). Kidneys of WT rats receiving HIP rat RBCs had increased stabilization of 
HIF-1α (Figure 6b) but no difference in HIF-2α levels (Figure 6c), compared with rats in the two control 
groups. 
To examine further a possible ‘amylin stress” on oxygen-sensing pathways, aggregated human amylin 
(hA) (0.08 μg/g body weight) was intravenously administered to diabetic UCD rats, daily, for one week. 
Intravenous infusion of aggregated human amylin in UCD rats led to amylin deposition on RBCs (Figure 
6d). This acute “amylin stress” provoked an increase in plasma EPO level (Figure 6e; the “after hA inj” 
rat group) and no difference in renal HIF-2α and HIF-1α levels in whole kidney tissue homogenate (Figure 
6f). Arginase 1 protein levels were elevated in kidney tissue homogenates from amylin-infused UCD rats, 
whereas there was no significant change of arginase 2 protein expression (Figure 6g). 
These data indicate elevated EPO and accumulation of HIFs in kidneys as a direct response to circulating 
amylin-coated RBCs (Figure 6h).
Discussion
We found that hypersecretion of human amylin is associated with amylin deposition in the 
microvasculature and RBCs leading to impaired RBC-capillary interaction and activation of hypoxia 
signaling pathways. Impairment of tissue oxygen-sensing found in diabetic HIP rats was mirrored in 
control rats that were given amylin-coated RBCs intravenously and in diabetic UCD rats that were given 
human amylin intravenously. These results indicate that amylin-coated RBCs are a trigger of hypoxia 
signaling pathways. These deleterious effects result in part from a reduced flux of amylin-coated RBCs 
through the capillaries that may involve adhesion proteins. Blocking the expression of adhesion proteins 
in the vascular endothelium by upregulation of EETs reduces amylin dyhomeostasis and HIF activation. 
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Future studies need to identify the ligand pairs for the amylin-mediated adhesive interaction between 
vascular ECs and RBCs. Candidate ligand pairs may include the VCAM-1-α4β1-integrin pair of proteins 
that appears to be involved in sickle cell disease40.   
This link between prediabetes-induced systemic amylin dyshomeostasis and tissue hypoxia has broad 
implications for health care because: 1) accumulating evidence demonstrates the presence of amylin 
deposition in vital organs21-31 and RBCs (as shown by the present human data) that may provide a 
therapeutic target reducing vascular injury prior the development of overt diabetes, 2) the public health 
impact of type-2 diabetes; and 3) the lack of drugs that counter amylin dyshomeostasis. 
Glycated hemoglobin has a higher affinity for oxygen than adult hemoglobin A (functional hemoglobin), 
and can disrupt the supply of oxygen to tissues41. Indeed, RBCs from hyperglycemic UCD rats have 
decreased deformability and functional hemoglobin compared with WT rats. RBC deformability and 
hemoglobin levels are even lower in HIP rats, which may explain, in part, the higher hypoxic response in 
control WT rats receiving RBCs from HIP rats compared to control rats receiving similar volumes of 
RBCs from UCD rats. 
Elevated EPO and microvascular dysfunction identify diabetic patients with increased risk of death42-44. 
In diabetic HIP rats, elevated plasma EPO does not correlate with an increase in hematocrit. HIP rat 
kidneys have amylin deposits in the microvasculature that co-localized with macrophage activation. Taken 
together, the results suggest that systemic amylin dyshomeostasis may upregulate eryptosis via 
macrophage activation. The results also indicate that amylin dyshomeostasis injures capillaries and is 
associated with inflammatory responses exacerbating ischemic vascular injury.
There are inherent limitations to our study of the interaction between pancreatic amylin secretion and 
RBCs. In the human study, we were not able to control for the potential effects of glucose, steroids, anti-
diabetic drugs or specific forms of anesthesia given to individual patients, which can affect pancreatic 
function including amylin and insulin secretion. 
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In conclusion, systemic amylin dyshomeostasis promotes amylin deposition in RBCs and the 
microvasculature associated with pathologic erythropoiesis, macrophage activation and macrophage 
accumulation in blood vessels. Future studies should determine whether the RBC amylin levels affect the 
course of microvascular complications.
Methods
Detailed Methods are included in Supplementary Materials.
Human studies
This research employed de-identified blood specimens matched with medical record data obtained from 
the biobank of the Center for Clinical and Translational Science at University of Kentucky. Sample 
collection and storage were approved by the Institutional Review Board. We assessed the relationship 
between HbA1c level and amylin concentration in RBC lysates from individuals with primary diagnosis 
of type-2 diabetes or diseases that are commonly associated with insulin resistance, including heart failure, 
cancer and stroke. RBC specimens were divided into groups based on the primary diagnosis of type-2 
diabetes, heart failure, cancer or stroke. Most humans in the heart failure and cancer groups had type-2 
diabetes as a second diagnosis. The negative control for amylin was RBC lysates from patients with over 
15 years of type-1 diabetes (and, therefore, depleted β-cell mass) who were otherwise healthy. The healthy 
control group included individuals without diabetes, heart failure, stroke or cancer. Exclusion criteria were 
based on conditions that may affect the pancreatic secretion of amylin such as transplant recipients (less 
than 6 months after the transplant), patients with liver disease, patients with HIV and pregnant or lactating 
women. Table 1 summarizes the diabetes status, co-morbidities, age, sex and body mass index (BMI) of 
the patients who provided the blood used in these analyses.
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Experimental Animals
All animal experiments conform to the NIH guide for the care and use of laboratory animals and were 
approved by the Institutional Animal Care and Use Committee at University of Kentucky. We compared 
rats that develop type-2 diabetes linked to expression of human amylin in the pancreas (HIP rats; n=65), 
with rats that develop type-2 diabetes in the absence of amyloid, as they express the non-amyloidogenic 
rat amylin (UCD rats; n=40) and control, non-diabetic rats (WT rats; n=53). 
Treatment
We performed a retrospective analysis of kidney tissue from a prior study22 in which HIP rats were treated 
for 10 weeks with a soluble epoxide inhibitor APAU (UC1153) added to their drinking water in order to 
upregulate the endogenous EET levels. APAU was formulated in polypropylene glycol at a concentration 
of 10 mg/mL with 30 minutes sonication. The APAU aliquot was added to the drinking water at a final 
content of 1%.  
Renal function analysis
Urine and blood were collected from rats in metabolic cages. Creatinine concentration in plasma and urine 
was measured using the kinetic Jaffé method45. Creatinine clearance (Ccr) was calculated using the 
formula: Ccr (ml/min) = (urine creatinine/plasma creatinine) × urine flow rate. Urinary albumin was 
measured by ELISA. 
Tissue extraction and RBC isolation
For measurements of hypoxia markers (hypoxia-inducible transcription factors 1α, HIF1-α, and 2α, HIF2-
α, arginase 1, arginase 2 and von Hippel-Lindau factor, vHL) and arginase activity, kidney tissue was 
extracted in PBS with protease and phosphatase inhibitors, followed by three consecutive cycles of 
freezing to -80°C and thawing. For other biochemical assays, tissues were extracted in homogenization 
buffer containing Triton X-100, SDS and protease and phosphatase inhibitors. 
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RBCs were isolated immediately after blood collection by centrifugation at 1,000g. For some experiments, 
RBCs were lysed in lysis buffer containing 10% NP-40. 
RBC transfusion
Isolated RBCs were combined with storage solution (150 mM HCl, 45 mM dextrose, 45.5 mM mannitol, 
and 2.2 mM adenine) in a 3:1 v/v ratio, transferred to sterile tubes and stored at 4°C in the dark before 
injection. Rats received 300 µL of pre-warmed (at 37º C) RBC solution once daily for 7 days via tail vein 
injection.
Hematocrit and hemoglobin measurements
Hematocrit was measured with an i-STAT analyzer using i-STAT CG8+ cartridges according to the 
manufacturer’s protocol. Hemoglobin content was calculated from the optical density at 405 nm.
Assessment of RBC shape and amylin deposition on RBCs by flow cytometry
RBCs were incubated with an anti-amylin antibody followed by incubation with an anti-rabbit Alexa 
Fluor® 488 secondary antibody. Flow cytometry was performed with a Becton Dickinson LSRII 
instrument. To assess cell shape, RBCs were first gated on a forward scatter (FSC)/side scatter (SSC) plot. 
The region 1 (R1) events were visualized using a FSC-A/FSC-H dot plot. For detecting amylin deposited 
on RBCs, cells were first gated on a forward scatter (FSC)/side scatter (SSC) plot. RBCs were further 
gated to determine the amylin signal (Alexa 488), using negative control (no antibody) and positive control 
(RBCs incubated with 50 μM of synthetic amylin peptide) to set the upper and lower boundaries. 
Immunofluorescence
Isolated RBCs were incubated with primary antibodies against human amylin and glycophorin A, 
followed by incubation secondary antibodies, and imaged with a Nikon A1R confocal microscope. For 
hemoglobin staining, blood smears on glass slide were fixed and incubated with primary antibodies against 
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hemoglobin and human amylin. Smears were then incubated with secondary antibodies, mounted in 
mounting media and imaged.
Biochemical assays
ELISA for human amylin, erythropoietin, HIF1-α, HIF2-α, arginase 1, arginase 2 and vHL were 
performed according to the manufacturer’s protocols. Arginase activity was measured in kidney 
homogenates using a colorimetric assay. Western blots were performed on plasma, WBC lysates, RBC 
lysates from humans and using a primary antibody against amylin and on kidney capillary lysates from 
rats using a primary antibody against VCAM-1 (1:1000, ab134047, Abcam). 
Immunohistochemistry
Immunohistochemical staining was performed on rat kidney slices using antibodies against amylin, 
collagen IV, IBA-1, and ED1). The staining area for amylin was analyzed in ImageJ. 
Statistical analysis
Statistical differences between groups were determined using Student’s t-test, one-way ANOVA or two-
way ANOVA, as appropriate. Multiple comparison and P values were calculated by Bonferroni correction 
for human data. P value for each regression analysis was calculated by the Spearman correlation test.
Disclosures: The authors have declared that no conflict of interest exists.
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Supplementary Materials
Supplementary Figure Legends
Supplementary Figure S1. Left) Representative western blot analysis of high molecular weight amylin 
oligomers in plasma, RBC lysate and white blood cell (WBC) lysate from an individual with type-2 
diabetes. (Right) The Ponceau S staining of the blot show in Left panel. 
Supplementary Figure S2. Representative images of Thioflavin S (green) and amylin (red) staining in 
the pancreas from a diabetic HIP and a control WT rat (n=3/group). Scale bar, 30 µm.
Supplementary Figure S3. Representative TEM images showing RBCs from HIP and WT rats, stained 
with human amylin primary antibody and gold (10nm) labelled secondary antibody. (Scale bar 1µm)
Supplementary Figure S4. PCD for WT rat RBCs and WT rat RBCs incubated ex vivo with oligomerized 
human amylin (n=5 preparations/group).
Supplementary Figure S5. Volume of urine excretion (A), albuminuria (B) and creatinine clearance rate 
(C) in 16 months old WT, diabetic UCD and diabetic HIP rats (n=6 rats/group). **P <0.01; ***P <0.001 
by One-way ANOVA.
Supplementary Figure S6. Gross spleen weights of 16 months old WT rats and diabetic HIP rats (n=10 
spleens/group). Data are means + SEM. *P <0.05
Supplementary Figure S7. Levels of von Hippel-Lindau (vHL) protein in the renal tissues from 16 
months old WT rats and diabetic HIP rats (n=5 rats/group). Data are means + SEM. 
Supplementary Figure S8. Western blot and ELISA analyses for VCAM-1 expression in kidney 
capillaries lysates of WT and HIP rats (n= 3 rats/group).
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Supplementary Figure S9. Reduced amylin deposition in kidneys correlated with partially reduced 
imbalance of arginase expression and arginase activation in HIP rat kidney tissues. (n=4 rats/group). Data 
are means + SEM. *P <0.05
Supplementary Methods
Supplementary References
Supplementary information is available at www.kidney-international.org
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Figure Legends
Fig. 1. Amylin-coated RBCs in human pathology. (a) Representative Western blots showing the amylin 
monomer in matched plasma, RBC and white blood cell (WBC) lysates from an individual with type-2 
diabetes. Recombinant human amylin served as control. (b) Whisker box plots comparing the 
concentration of amylin, measured by ELISA, in RBCs from healthy individuals (h; dark green; n=66) 
versus individuals with various diseases or combination thereof, including type-2 diabetes (T2D; blue; 
n=69), heart failure (HF) with diabetes (HF-T2D; dark red; n=49) and without diabetes (HF w/o T2D; 
light red; n=59), cancer with diabetes (C-T2D; black; n=33) and without diabetes (C; gray; n=58), and 
stroke (S; yellow; n=13). RBC lysates from patients with type 1 diabetes (T1D; black; n=5) are the 
negative control for amylin. Statistical significance of the differences in amylin level was assessed using 
One-way ANOVA with the Bonferroni post-test for comparing all pairs of columns. *P<0.05, **P <0.01, 
***P <0.001, ****P <0.0001. The correlation between RBC amylin and HbA1c in groups of healthy (c) 
and diseased individuals (d-i) described in (b). Out-of axis amylin-HbA1c levels: 25.2-5.8 and 12.2-4.6 in 
(d); 16.3-5.5 in (f) and 10.7-5.3 and 13.1-5.1 in (i), respectively. The Spearman nonparametric correlation 
analysis was performed in GraphPad and the values for the Spearman r and P are indicated on the plots. 
 
Fig. 2. Accumulation of amyloid-forming human amylin in RBCs from diabetic rats. (a) Amylin 
concentration, measured by ELISA, in matched plasma and lysates of WBCs and RBCs from HIP rats and 
WT littermates (n=4/group). (b) Representative flow cytometry graphs (upper) and mean intensity (lower) 
for amylin/Alexa Fluor 488 fluorescence in RBCs from healthy, prediabetic and diabetic HIP rats (n=5 
rats/group). (c) Amylin concentration in RBC lysates from 16 months old WT rats (n=7) and healthy 
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(n=6), prediabetic (n=15) and diabetic (n=16) HIP rats measured by ELISA. (d and e) Representative 
images of co-staining for amylin and hemoglobin (d) and amylin and glycophorin A (e) in RBCs from 
age-matched WT and diabetic HIP rats (n=3 rats/group). Scale bar, 10 µm (top row) and 5 µm (midle and 
bottom rows). (f) Representative STORM images showing RBCS from HIP and WT rats stained for human amylin 
(red) and Glycophorin A (green). (Scale bar 2µm). (n=3 for each rat group). *P <0.05; **P <0.01 by t-test (a) 
and One-way ANOVA (b and c).
 
Fig. 3. Pathophysiological changes induced by amyloid-forming amylin in RBCs. (a) Hemoglobin 
levels in RBCs from WT, HIP and UCD rats (n=11 rats/group). (b) Oxygen dissociation curve for RBCs 
from WT, HIP and UCD rats (n=5 rats/group). (c) Representative example of cell shape distribution of 
RBCs from WT (orange), UCD (blue) and HIP (pink) rats (n=6 rats/group) and the Pearson coefficient of 
dissymmetry (PCD) calculated from these data. (d) Percentage of RBC hemolysis in hypo-osmotic 
solutions. The NaCl concentration for 50% hemolysis of WT, HIP and UCD RBCs is indicated in the 
inset. (n=4 rats/group). (e and f) Representative images of co-staining for amylin and collagen IV (Col 
IV) in kidney tissue sections showing amylin deposition in arterioles and interstitial tissue (e) and in the 
glomerulus (f) in diabetic HIP rats but not in diabetic UCD rats (n=3 rats/group). (g) Representative 
images of co-staining for amylin and ionized calcium binding adaptor molecule 1 (IBA1) in kidney tissue 
sections from diabetic HIP and diabetic UCD rats (n=3 rats/group). (h) Representative images of staining 
for the cluster of differentiation 68 (CD68; ED1) in kidney tissue section from diabetic HIP and diabetic 
UCD rats (n=3 rats/group). (Scale bar 50µm) *P<0.05; **P<0.01 by One-way ANOVA with Tukey’s 
post-test (a and c). 
 
Fig. 4. Modulation of renal hypoxia markers by amylin dyshomeostasis. (a) EPO levels in plasma 
from 16 months WT rats (n=17), diabetic UCD rats (n=8) and diabetic HIP rats (n=17). (b) Percentage 
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number of reticulocytes over total numbers of RBCs in blood of WT, HIP and UCD rats (n=3 for each rat 
group). (c) Hematocrit levels in diabetic HIP and UCD rats and WT controls (n=6 rats/group). (d-h) 
Protein levels of HIF-1α (d), HIF-2α (e), arginase-1 (f) and arginase-2 (g) and arginase activity (h) 
measured by ELISA in renal tissues from 16 months old WT rats and diabetic UCD and HIP rats (n=10 
rats/group). *P <0.05; **P <0.01; ***P <0.001 by One-way ANOVA with Tukey’s post-test. 
 Fig. 5. Effect of increasing endogenous EETs on RBC-capillary coupling and renal hypoxia 
signaling. (a) Average numbers of RBCs adhered to cultured vascular endothelial cells when fixed 
hematocrit of RBCs flowed over cultured EC at constant rate for constant time of 20 minutes (n=3/ group). 
(b) Analysis of the adhesion of RBCs isolated from HIP rats and WT littermates to cultured vascular 
endothelial cells (n=8/group). (c) Adhesion of WT rat RBCs to cultured vascular endothelial cells 
with/without incubation with recombinant human amylin (50 μM) for 2 hours (n=5/group). (d) Attachment 
of RBCs from WT and diabetic HIP rats to vascular endothelial cells in the absence or in the presence of 
various amounts of EETs (n=8 rats/group). (e) Representative images of staining for amylin and Col IV 
in kidney sections from diabetic HIP rats (HIP-UT) and diabetic HIP rats with pharmacologically 
upregulated EETs (HIP-T). The scatterplot shows the percentage of the tissue area that is positive for 
amylin (n=3 rats/group). (f-g) Protein levels of HIF-2α (f) and HIF-1α (g) in whole kidney tissue 
homogenate from rats in the HIP-UT and HIP-T groups (n=4 rats/group). *P <0.05; **P <0.01; ***P 
<0.001 by t-test. 
 
Fig. 6. Altered oxygen sensing in kidneys following transfusion with amylin-loaded RBCs
(a) Plasma EPO levels in WT rats transfused with RBCs from i) WT rats (n=7); ii) diabetic UCD rats 
(n=7) and iii) diabetic HIP rats (n=7). (b and c) Protein levels of HIF-1α (b) and HIF-2α (c) in renal tissue 
homogenate from the rats described in (a). (d) Representative images of amylin and glycophorin A co-
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staining (left panel) and of amylin and hemoglobin co-staining (right panel) in RBCs from UCD rats 
infused with aggregated human amylin (daily injection of 0.08 μg/g body weight for 7 days; n=3 
rats/group). (e) Plasma EPO levels in diabetic UCD rats (n=3) at baseline and at the end of the acute 
intravenous treatment with aggregated human amylin (hA). (f-g) Protein levels of HIF-2α and HIF-1α 
 (f) and arginase-1 and arginase-2 (g) in renal tissue homogenates from diabetic UCD rats injected with 
human amylin versus non-injected diabetic UCD control rats (n=3 rats/group). (h) Cartoon illustrating the 
proposed mechanism through which “human” hyperamylinemia exacerbates hypoxia signalingin diabetic 
rats with pancreatic expression of non-amyloid forming amylin rat amylin (UCD rats). *P <0.05; **P 
<0.01; ***P <0.001 by One-way ANOVA with Tukey’s post-test (a-c) or two-tailed t-test (e-g).
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Table 1. Characteristics of the individuals providing the RBC samples, including age, sex, body 
mass index (BMI), diabetes status and co-morbidities.
Sample size n = 353
Disease Healthy (n=66)
(n+
Age 55±1 years 43±2 years
Female sex 127(45%) 29(45%)
Obesity (BMI>30) 116(41%) 14(21%)
Heart Failure 108(38%)
Type-2 Diabetes 69(24%)
Cancer 91(32%)
Stroke 13(5%)
Type-1 Diabetes 5(2%)
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CONCLUSION:
Diabetic Microcirculatory Disturbances and Pathologic 
Erythropoiesis Provoked by Deposition of Amyloid-Forming Amylin 
in Red Blood Cells and Capillaries
Diabetes-associated amylin 
dyshomeostasis promotes amylin 
deposition in red blood cells (RBCs) and 
capillaries leading to tissue hypoxic-
ischemic injury. 
Verma, 2019
amylin-coated 
RBCAMYLIN 
DYSHOMEOSTASIS
HIF-2α EPO
ERYTHROPOI
ESIS 
amylin coating 
RBCs
amylin deposition
in microvasculature
amylin 
dyshomestasis
endothelial cell-formed 
EETs
•   amylin (prediabetes)
• impaired clearance (  IDE)
• capillary dysfunction
• combined factors
HIF-2αHIF-1α;
arginase activity
 arginase 1, 2
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Supplementary Figures 
Supplementary Figure S1. (Left) Representative western blot analysis of high molecular weight 
amylin oligomers in plasma, RBC lysate and white blood cell (WBC) lysate from an individual 
with type-2 diabetes. (Right) The Ponceau S staining of the blot show in Left panel.
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Supplementary Figure S2. Representative images of Thioflavin S (green) and amylin (red) 
staining in the pancreas from a diabetic HIP and a control WT rat (n=3/group). Scale bar, 30 µm.
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Supplementary Figure S3. Representative TEM images showing RBCs from HIP and WT rats, 
stained with human amylin primary antibody and gold (10nm) labelled secondary antibody. (Scale 
bar 1µm)
HIP rat RBCs WR rat RBCs
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Supplementary Figure S4. PCD for WT rat RBCs and WT rat RBCs incubated ex vivo with 
oligomerized human amylin (n=5 preparations/group).
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Supplementary Figure S5. Volume of urine excretion (A), albuminuria (B) and creatinine 
clearance rate (C) in 16 months old WT, diabetic UCD and diabetic HIP rats (n=6 rats/group). **P 
<0.01; ***P <0.001 by One-way ANOVA.
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Supplementary Figure S6. Gross spleen weights of 16 months old WT rats and diabetic HIP rats 
(n=10 spleens/group). Data are means + SEM. *P <0.05
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Supplementary Figure S7. Levels of von Hippel-Lindau (vHL) protein in the renal tissues from 
16 months old WT rats and diabetic HIP rats (n=5 rats/group). Data are means + SEM. 
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Supplementary Figure S8. Western blot and ELISA analyses for VCAM-1 expression in kidney 
capillaries lysates of WT and HIP rats (n= 3 rats/group).
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Supplementary Figure S9. Reduced amylin deposition in kidneys correlated with partially 
reduced imbalance of arginase expression and arginase activation in HIP rat kidney tissues. (n=4 
rats/group). Data are means + SEM. *P <0.05
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Supplementary Figures 
Supplementary Figure S1. (Left) Representative western blot analysis of high molecular weight 
amylin oligomers in plasma, RBC lysate and white blood cell (WBC) lysate from an individual 
with type-2 diabetes. (Right) The Ponceau S staining of the blot show in Left panel.
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Supplementary Figure S2. Representative images of Thioflavin S (green) and amylin (red) 
staining in the pancreas from a diabetic HIP and a control WT rat (n=3/group). Scale bar, 30 µm.
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Supplementary Figure S3. Representative TEM images showing RBCs from HIP and WT rats, 
stained with human amylin primary antibody and gold (10nm) labelled secondary antibody. 
(Scale bar 1µm)
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Supplementary Figure S4. PCD for WT rat RBCs and WT rat RBCs incubated ex vivo with 
oligomerized human amylin (n=5 preparations/group).
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Supplementary Figure S5. Volume of urine excretion (A), albuminuria (B) and creatinine 
clearance rate (C) in 16 months old WT, diabetic UCD and diabetic HIP rats (n=6 rats/group). 
**P <0.01; ***P <0.001 by One-way ANOVA.
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Supplementary Figure S6. Gross spleen weights of 16 months old WT rats and diabetic HIP 
rats (n=10 spleens/group). Data are means + SEM. *P <0.05
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Supplementary Figure S7. Levels of von Hippel-Lindau (vHL) protein in the renal tissues from 
16 months old WT rats and diabetic HIP rats (n=5 rats/group). Data are means + SEM. 
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Supplementary Figure S8. Western blot and ELISA analyses for VCAM-1 expression in 
kidney capillaries lysates of WT and HIP rats (n= 3 rats/group).
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Supplementary Figure S9. Reduced amylin deposition in kidneys correlated with partially 
reduced imbalance of arginase expression and arginase activation in HIP rat kidney tissues. (n=4 
rats/group). Data are means + SEM. *P <0.05
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Supplemental Methods
Human studies 
This research employed de-identified blood specimens matched with medical record data obtained 
from the biobank of the Center for Clinical and Translational Science at University of Kentucky 
(UK-CCTS). Sample collection and storage was approved by the Institutional Review Board at the 
University of Kentucky. Written informed consent was received from each individual prior to 
donating the blood sample. Specimens from transplant recipients (less than 6 months from the 
transplant), patients with liver disease, patients with HIV and pregnant or lactating women, which 
may affect the pancreatic secretion of amylin, were excluded from the study. RBCs from patients 
with type-2 diabetes were the amylin positive control, whereas patients with over 15 years of type-
1 diabetes (and, therefore, depleted β-cell mass) but otherwise healthy served as the negative 
control for amylin. The latter samples were collected under a different IRB-approved protocol and 
de-identified.
RBC specimens were divided into groups based on the primary diagnosis of heart failure, cancer 
or stroke. Most individuals in the disease group had type-2 diabetes as the second diagnosis. 
Diabetes status, co-morbidities and characteristics of the individuals providing the blood samples, 
such as age, sex and body mass index (BMI) are summarized in Table 1. The control group 
represents individuals without diabetes, heart failure, stroke or cancer. 
Statistics and defining and handling of outliers for the human study
The Spearman nonparametric correlation analysis was used to examine the relationship between 
RBC amylin levels and HbA1c (Fig 1c-i), respectively, in healthy individuals and disease groups. 
We computed the Whisker plot (Fig 1b) from amylin levels in human RBC across different groups. 
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In each group, the median, first and third quartiles were calculated. The interquartile range was 
calculated by subtracting the lower quartile value from the upper quartile value. Points falling more 
than 1.5 times the interquartile range above the third quartile were considered outliers. The outliers 
were indicated in the caption of Figure 1 and included in statistical analyses. One-way ANOVA 
with the Bonferroni post-test was used to compare amylin levels in the 8 groups. All analyses were 
performed using GraphPad Prism 5.0 software.
Hemoglobin A1c (HbA1c) measurement
Hemoglobin A1c or HbA1c levels were measured in human blood samples by A1CNow+ kit 
(Polymer Technology Systems,Inc. IN, USA) as per manufacturer’s protocol provided with the 
kit..
Animal studies 
Experimental Animals
All animal experiments were approved by the Institutional Animal Care and Use Committee at 
University of Kentucky and conforms to the Guide for the Care and Use of Laboratory Animals, 
the 8th Edition, published by the National Academies Press, Washington (DC); 2011. We compared 
rats that develop type-2 diabetes (T2D) linked to expression of human amylin in the pancreas (HIP 
rats; n=65) with rats that develop T2D in the absence of amyloid, as they express solely the non-
amyloid forming rat amylin (UCD rats; n=40) and control, non-diabetic rats (WT rats; n=53). Only 
males were used because HIP females become diabetic at a more advanced age. S1,S2
HIP rats are Sprague-Dawley (SD) rats that overexpress (3-fold) human amylin specifically 
in the pancreatic β-cells on the insulin II promoter.S1 HIP rats develop amylin dyshomeostasis and 
amylin amyloid deposition in pancreatic islets leading to β-cell apoptosis and hyperglycemia with 
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regular diet. Breeding pairs were obtained from Charles River Laboratory. The presence of the 
human amylin gene was confirmed by genotyping using the following primers:
Rip1: 5’- GTC ATG TGC ACC TAA AGG GGC AAG TAA TTC A-3’
Rip2: 5’- CGA GTG GGC TAT GGG TTT GT -3’
Mus-a-actinF1: 5’-CAC CAC ACC TTC TAC AAT GAG CTG-3’  
Mus-a-actinR1: 5’-TCA TCA GGT AGT CAG TGA GGT CGC -3’ 
Actin was used as the internal control. WT littermates were used as the non-diabetic control. 
UCD rats were generated as described in Ref 3 by crossing obese Sprague-Dawley rats 
with Zucker diabetic fatty (ZDF) lean rats.  ZDF-lean founder rats were purchased from Charles 
River Laboratories. These rats have functional leptin receptors and the autosomal recessive β-cell 
defect.S3 The breeding strategy was to maintain the obese phenotype from obese Sprague-Dawley 
rats and selecting for individuals homozygous for the autosomal recessive β-cell defect. In the 
seventh generation (F7) all animals were homozygous for the β-cell defect and increased genetic 
propensity to develop diabetes. 
Rats were housed (singly) in individually ventilated cages (ACE, Allentown, NJ, USA) 
with Sani-Chip bedding (Harlan-Teklad) and maintained on a standard chow diet (Teklad Global 
18% Protein Rodent Diet #2018, VA, USA) and reverse osmosis drinking water for the duration 
of the study. Nesting material (Enviro-Dri®, Shepherd Specialty Papers) and aspen chew blocks 
(Lomir Biomedical Inc. IL,USA) were provided for environmental enrichment. All animals were 
maintained on a 12:12 hour light:dark cycle at temperatures between 21-24 ºC. 
Treatment
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We performed a retrospective analysis of kidney tissue from HIP rats with pharmacologically 
elevated EETs used in a prior study.S4 Briefly, pre-diabetic male HIP rats were randomized to 
treatment (HIP-T) and no treatment (HIP-UT) groups by a blinded observer. To increase the 
endogenous levels of EETs, pre-diabetic HIP rats were treated with a soluble epoxide hydrolase 
inhibitor APAU (UC1153) added in drinking water for 10 weeks. APAU was formulated in 
polypropylene glycol at a concentration of 10 mg/mL with 30 minutes sonication. The APAU 
aliquot was added to the drinking water at a final content of 1%. 
Renal function analysis
Rats were placed in metabolic cages. After 2 days of acclimation, 24-hours cycle urine collections 
were taken at baseline and day 2. Blood sampling (500 μl) was obtained from tail vein for 
determination of creatinine level. Creatinine concentration in plasma and urine was measured 
using the kinetic Jaffé methodS5 with 10% picric acid solution in NaOH. After 15 min, absorbance 
reading was obtained in a microplate set for dual wavelengths at 490 nm (read) and 620 nm 
(reference). Creatinine clearance (Ccr) was calculated using the following formula: Ccr (ml/min) 
= (urine creatinine/plasma creatinine) × urine flow rate. Urinary excretion rate of albumin was 
measured using a commercially available ELISA kit (E110-125, Bethil Laboratories, Inc, TX).
Tissue extraction and red blood cell (RBC) isolation
For measurements of hypoxia markers (HIF-1α, HIF-2α, Arginase 1, Arginase 2 and vHL) by 
ELISA and arginase activity assay, tissues were extracted in 1xPBS with 1% (v/v) protease and 
phosphatase inhibitors. The homogenate was frozen at -80°C and thawed on ice for 3 consecutive 
cycles to break cell membranes. For other biochemical assays, tissues were extracted in 
homogenization buffer (150 mM NaCl, 50 mM Tris, 50 mM NaF, 2% Triton X-100, 0.1% SDS 
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and 1% (v/v) protease and phosphatase inhibitors). All homogenates were then centrifuged at 
17,000 xg for 30 minutes at 4oC. 
Rat blood samples were collected into sterile K2-EDTA vacutainer tubes. RBCs were 
isolated from plasma by centrifugation at 1,000 xg for 10 minutes, at 4°C, immediately after blood 
collection. To obtain RBCs lysates for biochemical analyses, RBCs were incubated with cell lysate 
buffer (10% NP-40, 150 mM NaCl, 10 mM Tris, 2 mM EGTA and 50 mM NaF, 1% (v/v) protease 
and phosphatase inhibitors) for 30 minutes on the rotor at 40C, followed by centrifugation at 17000 
xg for 30 minutes at 4oC. Supernatant was used for experiments.
RBC transfusion
RBCs were isolated into a heparin lithium tube, washed twice with sterile 1xPBS, combined with 
storage solution (150 mM HCl, 45 mM dextrose, 45.5 mM mannitol, and 2.2 mM adenine) in a 
3:1 v/v ratio, transferred to sterile tubes and stored at 4°C in the dark before injection. Rats received 
300 µL of pre-warmed (at 37º C) RBCs solution onc  daily for 7 days via tail vein injection. 
Hematocrit measurements
The ratio of RBCs to total blood volume (hematocrit; Hct) was measured with an i-SATA analyzer 
(VetScan i-STAT 1 Handheld Analyzer, ABAXIS, CA, USA) using i-STAT CG8+ cartridges 
(VetScan i-SATA CG8+ cartridge, Cat# 600-9001-25, ABAXIS) according to the manufacturer’s 
protocol. 
Hemoglobin measurements
Isolated RBCs were first suspended to a hematocrit 2.5% in Hank’s Balanced Salt Solution (HBSS) 
containing 0.5% BSA (HBSS/A). 10 µL of RBCs suspension was further diluted in 990 µL 
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HBSS/A and 100 µL of this RBCs dilution was incubated with 200 µL 0.5% SDS for 5 hours. 
Total hemoglobin in the 100 µL RBCs diluted suspension was calculated from the optical density 
(at 540 nm) measured with a spectrophotometer (Molecular Devices, Menlo Park, CA, USA).
Assessment of RBC shape and amylin deposition on RBCs by flow cytometry
RBCs (1x107 cells) were aliquoted to assay tubes, washed twice with 2 mL incubation buffer (0.5 
% BSA in PBS), and resuspended in 100 µL incubation buffer. RBCs were incubated with an anti-
amylin antibody (1:200, T-4157, Bachem-Peninsula Laboratories, CA, USA) for 1 hour on ice, 
washed twice with PBS by centrifugation at 1000 xg for 1 minute and then incubated with goat 
anti-rabbit Alexa Fluor® 488 (A11029, Invitrogen, MA, USA) for 30 min on ice. RBCs were then 
washed twice before re-suspension in 200 µl PBS, and analyzed by flow cytometer (Becton 
Dickinson LSRII) within 90 min. To assess the cell shape, RBCs were first gated on a forward 
scatter (FSC)/side scatter (SSC) plot. The R1 events are visualized using a FSC-A/FSC-H dot plot. 
For detecting amylin deposited on RBCs, the cells were first gated on a forward scatter (FSC)/side 
scatter (SSC) plot. RBCs were further gated to determine the amylin signal (Alexa 488), using 
negative control (no antibody) and positive control to set the upper and lower boundaries. 
RBC adhesion assay
Adult rat microvascular endothelial cells (RA-6024, Cell Biologics, IL, USA) were cultured on 
96-wells cell culture plate coated with cell attachment factor solution (123-100, Sigma, MO, USA). 
Cells were allowed to attach for 24 hours and used for experiments when they reached 70%-90% 
confluency. Isolated RBCs were washed twice with cold HBSS and once with HBSS/A. RBCs 
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were suspended to hematocrit 2.5% in HBSS/A. 10µL of RBCs suspension was used to measure 
the hemoglobin content as described above. Another 300µL of RBC suspension aliquot 
(hematocrit 2.5% in HBSS/A) was gently layered on confluent endothelial cells pre-incubated with 
150 µL of media containing different concentrations of (±)14(15)-EET (50651, Cayman Chemical, 
MI). The plate was incubated at 37° C for 40 min. An additional 83 µL of HBSS/A was gently 
added to create a slight convex meniscus over each well, and the plate was covered with an 
adhesive plastic film (89087-692, VWR, IL, USA). The plate was then inverted and allowed to sit 
for an additional 30 min at 37° C. With the plate maintained in the inverted position, the adhesive 
sheet was removed and the remaining fluid was removed by aspiration. 200 µL 0.5% SDS was 
added to each well, followed by 5 hours incubation at room temperature. The amount of 
hemoglobin in each well was measured from the optical density (OD) as described above. 
Adherence was calculated as the percentage of OD of adhered hemoglobin/ (OD of total 
hemoglobin x dilution factor).
RBC adherence assay in flow condition
Freshly isolated red blood cells were diluted to 0.5 hematocrit in saline solution and passed at a 
fixed rate for 20 minutes over endothelial cells plated on a coverslip in recording and imaging 
chamber (ALA scientific instruments). The coverslip was then mounted over a glass slide and the 
number of RBCs attached to endothelial cells was counted under light microscope at 10 different 
places on coverslip.
Immunofluorescence
Isolated RBCs were washed 3 times with 1xPBS, blocked with 10% goat serum for 15 minutes at 
37o C, incubated with primary antibodies against human amylin (1:200, T-4157, Bachem-
Peninsula Laboratories) and Glycophorin A (1:100, sc-71159, Santa Cruz Biotechnology, TX, 
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USA) for 15 min at 37o C, followed by incubation with anti-mouse IgG and anti-rabbit IgG 
secondary antibodies for 15 min at 37o C. Cells were hemolyzed in 1% saponin in PBS, centrifuged 
at 8000g for 5 min and the pellet was re-suspended in 1xPBS for microscopy. Images were 
obtained on a Nikon A1R confocal microscope (Nikon, NY, USA).
For hemoglobin staining, blood smears on glass slide were fixed in 
acetone/ethanol/methanol (6:2:2) for 20 minutes at RT. Smears were air-dried and re-hydrated in 
1xPBS for 5 minutes, rinsed briefly in distilled water, and incubated with pre warmed (37oC) 
trypsin solution (0.1% in calcium chloride 0.1% pH 7.8) for 15 minutes in humidity chamber. 
Next, smears were washed in PBS for 5 minutes with gentle agitation, rinsed in distilled water and 
air dried. Smears were then incubated at 37oC with primary antibodies against hemoglobin (1:100, 
ab92492, Abcam, MA, USA) and human amylin (1:100, SC-377530, Santa Cruz Biotech, TX, 
USA) in humidity chamber for 30-40 minutes. They were next washed, air-dried and covered with 
anti-mouse IgG and anti-rabbit IgG secondary antibodies for 20-30 minutes at 37oC. After 
incubation smears were washed with PBS, rinsed in water, air dried and mounted in mounting 
media. Thin sections of paraffin embedded pancreatic tissues were co-stained with Thioflavin S 
and an anti-amylin antibody. 
Enzyme-linked immunosorbent assay (ELISA)
ELISA assays for human amylin (EZHA-52K, Millipore, MA; EIA-AMY-5, Raybiotech, GA, 
USA), erythropoietin (EPO; 442807, Biolegend, CA, USA), hypoxia-inducible transcription factor 
1α (HIF1-α; MBS764727, MyBioSource, CA, USA), hypoxia-inducible transcription factor 2α 
(HIF2-α; MBS2601406, MyBioSource), arginase 1 (MBS289817, MyBioSource), arginase 2 
(MBS7216305, MyBioSource), von Hippel-Lindau (vHL; MBS288882, MyBioSource) and 
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VCAM-1 (LS-F24285, LifeSpan BioSciences, Inc, WA, USA) were performed according to the 
manufacturer’s protocols..
Arginase activity assay
Arginase activity was measured in kidney homogenates using a colorimetric assay (MAK112, 
Sigma, MO, USA). To eliminate urine from kidney samples, 300µL of kidney homogenate were 
filtered through a 10kD spin column (88513, ThermoFisher, MA, USA) with centrifugation at 
15000g for 60 min, 4oC. Collected remnant was used for experiments. Assay was performed 
according to the manufacturer’s protocol. Briefly, filtered kidney samples were incubated with 
reaction substrate mix for 2 hours at 37o C. The stop solution was applied, followed by incubation 
at 37o C for 35 min. Absorbance reading was taken at 430 nm. Arginase activity was calculated 
based on manufacturer’s analysis instruction. 
Isolation of kidney capillaries 
Kidney capillaries were isolated by using the protocol used for the isolation of brain capillaries as 
describes previouslyS2. Briefly, kidneys were homogenized in ice cold cPBS and were mixed with 
30% Ficoll solution by gently inverting tubes and then centrifuged 5800g for 20 minutes at 4oC.  
Pellets were re-suspended in ice cold cPBS with 1%BSA and were passed through the glass beads 
column. Beads were agitated in cPBS with 1%PBS using 25mL pipette and solutions were taken 
equally in two 50mL tubes. Tubes were centrifuged and pellets were dissolved in 0.5 to 1mL cPBS 
and used for experiment. 
Immunoblot
Western blot analysis was performed on plasma, WBC lysates, and RBC lysates from humans 
using a primary antibody against amylin (1:2,000, T-4157, Bachem-Peninsula Laboratories). 
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Western blot analysis for VCAM-1 (1:1000, ab134047, Abcam) was done on kidney capillary 
lysates from WT and HIP rats
Immunohistochemistry
Immunohistochemical staining was performed on rat kidney slices using antibodies against amylin 
(1:200, SC-377530, Santa Cruz), collagen IV (1:1000, ab6586, Abcam), IBA-1(1:200, 019-19741, 
Wako, VA, USA), and EDI (1:100, MCA341GA, Biorad, PA, USA). Biotinylated anti-mouse 
(1:400, BA2000, Vector lab, CA, USA), AP conjugated anti-mouse and anti-rabbit IgG (1:50, 
A3562, A3687, Sigma) were the secondary antibodies. The staining area for amylin was analyzed 
by ImageJ. The imaging area is 1280 x 1024 pixels; 1 pixel2 is 0.053 µm2 for 40X objective lens.
Transmission electron microscopy
Fresh red blood cells were fixed in 0.1M Sorensen’s phosphate buffer with 4% PFA and 0.2% 
glutaraldehyde for 1-2 hours. Cells were then washed in 0.1M Sorensen’s buffer and blocked in 
0.1% sodium borohydride for 15 minutes and incubated in AURION blocking solution (AURION 
blocking solution, 50-247-65, fisher scientific) for 60 minutes. Cells were washed with incubation 
buffer and incubated with primary antibody (anti-human amylin; T-4157; Peninsula lab) for 2 
hours at RT. Cells were rinsed with incubation buffer and incubated with secondary antibody (anti-
Rabbit IgG-10nm Gold; ab27234, Abcam) overnight at 4 ºC. Cells were then washed in PBS and 
post-fixed in 2% glutaraldehyde for 2 hours. Cells were silver stained using Silver enhancement 
kit (ab170732, Abcam) and fixed in 0.5% OsO4 in 0.1M Sorensen’s buffer for 15 minutes. Cells 
were embedded in Epoxy resin and thin sections were prepared over nickel grid (T300-Ni, Electron 
microscopy science) for imaging in Transmission Electron Microscope (FEI Talos F200X, Thermo 
Scientific).
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High resolution Stochastic Optical Reconstruction Microscopy (STORM)
Fresh red blood cells were stained using the same protocol as for immunofluorescence using 
primary antibodies (anti-human amylin; T-4157; Peninsula lab and anti-glycophorin A; sc-
71159Santacuz biotech) and secondary antibodies (rabbit IgG-atto 647 and mouse IgG-atto 488). 
Cells were kept in STORM imaging buffer {7µl GLOX (oxygen scavenger)+ 70µl of MEA 
(Cysteamine hydrochloride)+ 620µl of buffer B (Tris-HCL/NaCl)} during imaging on Nikon N-
SIM N-STORM (Nikon) microscope.
RBCs osmotic resistance test
The osmotic resistance of RBCs was assessed by measuring hemolysis at various concentrations 
of NaCl. Solutions with NaCl concentrations between 0 and 9g/L were obtained by mixing normal 
saline solution (containing 9g/L NaCl) with distilled water in various proportions. 285µl of each 
solution was placed in an Eppendorf tube. 4µl of RBC lysate was then added to tubes, mixed and 
incubated at room temperature for 30 min. The tubes were then centrifuged at 600 × g for 5 min. 
The supernatant was collected and the amount of hemoglobin released was detected by measuring 
the O.D. at 540 nm. For each sample, the % hemolysis at a given NaCl concentration was 
calculated assuming that complete hemolysis occurs in distilled water. All samples were run in 
duplicate.
Oxygen dissociation curve
Fresh heparinized blood was oxygenated by blowing air on its surface in small vessels with 
swirling for a few seconds. 200µl of buffer (20mM phosphate in isotonic NaCl) was pipetted in a 
XF96 plate (Agilent Technologies, CA, USA) and 4µl of blood and 4µl of active yeast cell 
suspension were added to each well. The partial pressure of oxygen was then recorded at different 
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time points in a Seahorse XF96 Extracellular Flux Analyzer (Agilent Technologies, CA, USA) 
until 100% oxygen consumption. Percentage saturation was then calculated and oxygen 
dissociation curve was plotted as described previouslyS6.
Reticulocyte count
For reticulocyte counting, 2-3 drops of filtered new methylene blue solution (New methylene blue 
1g, sodium citrate 0.6g, sodium chloride 0.7g and distilled water 100ml) mixed with equal amount 
of blood and incubated at 37ºC for 15 minutes. After gentle mixing, thin smear of blood was 
prepared in glass slide and air dried.  Reticulocytes and RBCs were counted under a light 
microscope and the percentage of reticulocytes relative to the total number of RBCs was 
calculated.
Statistical analysis for animal data
Statistical differences between groups were determined using student’s t-test, one-way ANOVA 
or two-way ANOVA, as appropriate. Data are presented as mean ± standard error. Differences 
between groups were considered significant when P <0.05. All analyses were performed using 
GraphPad Prism 5.0 software.
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Supplemental Methods
Human studies 
This research employed de-identified blood specimens matched with medical record data 
obtained from the biobank of the Center for Clinical and Translational Science at University of 
Kentucky (UK-CCTS). Sample collection and storage was approved by the Institutional Review 
Board at the University of Kentucky. Written informed consent was received from each 
individual prior to donating the blood sample. Specimens from transplant recipients (less than 6 
months from the transplant), patients with liver disease, patients with HIV and pregnant or 
lactating women, which may affect the pancreatic secretion of amylin, were excluded from the 
study. RBCs from patients with type-2 diabetes were the amylin positive control, whereas 
patients with over 15 years of type-1 diabetes (and, therefore, depleted β-cell mass) but otherwise 
healthy served as the negative control for amylin. The latter samples were collected under a 
different IRB-approved protocol and de-identified.
RBC specimens were divided into groups based on the primary diagnosis of heart failure, cancer 
or stroke. Most individuals in the disease group had type-2 diabetes as the second diagnosis. 
Diabetes status, co-morbidities and characteristics of the individuals providing the blood 
samples, such as age, sex and body mass index (BMI) are summarized in Table 1. The control 
group represents individuals without diabetes, heart failure, stroke or cancer. 
Statistics and defining and handling of outliers for the human study
The Spearman nonparametric correlation analysis was used to examine the relationship between 
RBC amylin levels and HbA1c (Fig 1c-i), respectively, in healthy individuals and disease 
groups. We computed the Whisker plot (Fig 1b) from amylin levels in human RBC across 
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different groups. In each group, the median, first and third quartiles were calculated. The 
interquartile range was calculated by subtracting the lower quartile value from the upper quartile 
value. Points falling more than 1.5 times the interquartile range above the third quartile were 
considered outliers. The outliers were indicated in the caption of Figure 1 and included in 
statistical analyses. One-way ANOVA with the Bonferroni post-test was used to compare amylin 
levels in the 8 groups. All analyses were performed using GraphPad Prism 5.0 software.
Hemoglobin A1c (HbA1c) measurement
Hemoglobin A1c or HbA1c levels were measured in human blood samples by A1CNow+ kit 
(Polymer Technology Systems,Inc. IN, USA) as per manufacturer’s protocol provided with the 
kit..
Animal studies 
Experimental Animals
All animal experiments were approved by the Institutional Animal Care and Use Committee at 
University of Kentucky and conforms to the Guide for the Care and Use of Laboratory Animals, 
the 8th Edition, published by the National Academies Press, Washington (DC); 2011. We 
compared rats that develop type-2 diabetes (T2D) linked to expression of human amylin in the 
pancreas (HIP rats; n=65) with rats that develop T2D in the absence of amyloid, as they express 
solely the non-amyloid forming rat amylin (UCD rats; n=40) and control, non-diabetic rats (WT 
rats; n=53). Only males were used because HIP females become diabetic at a more advanced 
age. S1,S2
HIP rats are Sprague-Dawley (SD) rats that overexpress (3-fold) human amylin 
specifically in the pancreatic β-cells on the insulin II promoter.S1 HIP rats develop amylin 
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dyshomeostasis and amylin amyloid deposition in pancreatic islets leading to β-cell apoptosis 
and hyperglycemia with regular diet. Breeding pairs were obtained from Charles River 
Laboratory. The presence of the human amylin gene was confirmed by genotyping using the 
following primers:
Rip1: 5’- GTC ATG TGC ACC TAA AGG GGC AAG TAA TTC A-3’
Rip2: 5’- CGA GTG GGC TAT GGG TTT GT -3’
Mus-a-actinF1: 5’-CAC CAC ACC TTC TAC AAT GAG CTG-3’  
Mus-a-actinR1: 5’-TCA TCA GGT AGT CAG TGA GGT CGC -3’ 
Actin was used as the internal control. WT littermates were used as the non-diabetic control. 
UCD rats were generated as described in Ref 3 by crossing obese Sprague-Dawley rats 
with Zucker diabetic fatty (ZDF) lean rats.  ZDF-lean founder rats were purchased from Charles 
River Laboratories. These rats have functional leptin receptors and the autosomal recessive β-cell 
defect.S3 The breeding strategy was to maintain the obese phenotype from obese Sprague-
Dawley rats and selecting for individuals homozygous for the autosomal recessive β-cell defect. 
In the seventh generation (F7) all animals were homozygous for the β-cell defect and increased 
genetic propensity to develop diabetes. 
Rats were housed (singly) in individually ventilated cages (ACE, Allentown, NJ, USA) 
with Sani-Chip bedding (Harlan-Teklad) and maintained on a standard chow diet (Teklad Global 
18% Protein Rodent Diet #2018, VA, USA) and reverse osmosis drinking water for the duration 
of the study. Nesting material (Enviro-Dri®, Shepherd Specialty Papers) and aspen chew blocks 
(Lomir Biomedical Inc. IL,USA) were provided for environmental enrichment. All animals were 
maintained on a 12:12 hour light:dark cycle at temperatures between 21-24 ºC. 
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Treatment
We performed a retrospective analysis of kidney tissue from HIP rats with pharmacologically 
elevated EETs used in a prior study.S4 Briefly, pre-diabetic male HIP rats were randomized to 
treatment (HIP-T) and no treatment (HIP-UT) groups by a blinded observer. To increase the 
endogenous levels of EETs, pre-diabetic HIP rats were treated with a soluble epoxide hydrolase 
inhibitor APAU (UC1153) added in drinking water for 10 weeks. APAU was formulated in 
polypropylene glycol at a concentration of 10 mg/mL with 30 minutes sonication. The APAU 
aliquot was added to the drinking water at a final content of 1%. 
Renal function analysis
Rats were placed in metabolic cages. After 2 days of acclimation, 24-hours cycle urine 
collections were taken at baseline and day 2. Blood sampling (500 μl) was obtained from tail 
vein for determination of creatinine level. Creatinine concentration in plasma and urine was 
measured using the kinetic Jaffé methodS5 with 10% picric acid solution in NaOH. After 15 min, 
absorbance reading was obtained in a microplate set for dual wavelengths at 490 nm (read) and 
620 nm (reference). Creatinine clearance (Ccr) was calculated using the following formula: Ccr 
(ml/min) = (urine creatinine/plasma creatinine) × urine flow rate. Urinary excretion rate of 
albumin was measured using a commercially available ELISA kit (E110-125, Bethil 
Laboratories, Inc, TX).
Tissue extraction and red blood cell (RBC) isolation
For measurements of hypoxia markers (HIF-1α, HIF-2α, Arginase 1, Arginase 2 and vHL) by 
ELISA and arginase activity assay, tissues were extracted in 1xPBS with 1% (v/v) protease and 
phosphatase inhibitors. The homogenate was frozen at -80°C and thawed on ice for 3 
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consecutive cycles to break cell membranes. For other biochemical assays, tissues were extracted 
in homogenization buffer (150 mM NaCl, 50 mM Tris, 50 mM NaF, 2% Triton X-100, 0.1% 
SDS and 1% (v/v) protease and phosphatase inhibitors). All homogenates were then centrifuged 
at 17,000 xg for 30 minutes at 4oC. 
Rat blood samples were collected into sterile K2-EDTA vacutainer tubes. RBCs were 
isolated from plasma by centrifugation at 1,000 xg for 10 minutes, at 4°C, immediately after 
blood collection. To obtain RBCs lysates for biochemical analyses, RBCs were incubated with 
cell lysate buffer (10% NP-40, 150 mM NaCl, 10 mM Tris, 2 mM EGTA and 50 mM NaF, 1% 
(v/v) protease and phosphatas  inhibitors) for 30 minutes on the rotor at 40C, followed by 
centrifugation at 17000 xg for 30 minutes at 4oC. Supernatant was used for experiments.
RBC transfusion
RBCs were isolated into a heparin lithium tube, washed twice with sterile 1xPBS, combined with 
storage solution (150 mM HCl, 45 mM dextrose, 45.5 mM mannitol, and 2.2 mM adenine) in a 
3:1 v/v ratio, transferred to sterile tubes and stored at 4°C in the dark before injection. Rats 
received 300 µL of pre-warmed (at 37º C) RBCs solution once daily for 7 days via tail vein 
injection. 
Hematocrit measurements
The ratio of RBCs to total blood volume (hematocrit; Hct) was measured with an i-SATA 
analyzer (VetScan i-STAT 1 Handheld Analyzer, ABAXIS, CA, USA) using i-STAT CG8+ 
cartridges (VetScan i-SATA CG8+ cartridge, Cat# 600-9001-25, ABAXIS) according to the 
manufacturer’s protocol. 
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Hemoglobin measurements
Isolated RBCs were first suspended to a hematocrit 2.5% in Hank’s Balanced Salt Solution 
(HBSS) containing 0.5% BSA (HBSS/A). 10 µL of RBCs suspension was further diluted in 990 
µL HBSS/A and 100 µL of this RBCs dilution was incubated with 200 µL 0.5% SDS for 5 
hours. Total hemoglobin in the 100 µL RBCs diluted suspension was calculated from the optical 
density (at 540 nm) measured with a spectrophotometer (Molecular Devices, Menlo Park, CA, 
USA).
Assessment of RBC shape and amylin deposition on RBCs by flow cytometry
RBCs (1x107 cells) were aliquoted to assay tubes, washed twice with 2 mL incubation buffer 
(0.5 % BSA in PBS), and resuspended in 100 µL incubation buffer. RBCs were incubated with 
an anti-amylin antibody (1:200, T-4157, Bachem-Peninsula Laboratories, CA, USA) for 1 hour 
on ice, washed twice with PBS by centrifugation at 1000 xg for 1 minute and then incubated with 
goat anti-rabbit Alexa Fluor® 488 (A11029, Invitrogen, MA, USA) for 30 min on ice. RBCs 
were then washed twice before re-suspension in 200 µl PBS, and analyzed by flow cytometer 
(Becton Dickinson LSRII) within 90 min. To assess the cell shape, RBCs were first gated on a 
forward scatter (FSC)/side scatter (SSC) plot. The R1 events are visualized using a FSC-A/FSC-
H dot plot. For detecting amylin deposited on RBCs, the cells were first gated on a forward 
scatter (FSC)/side scatter (SSC) plot. RBCs were further gated to determine the amylin signal 
(Alexa 488), using negative control (no antibody) and positive control to set the upper and lower 
boundaries. 
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RBC adhesion assay
Adult rat microvascular endothelial cells (RA-6024, Cell Biologics, IL, USA) were cultured on 
96-wells cell culture plate coated with cell attachment factor solution (123-100, Sigma, MO, 
USA). Cells were allowed to attach for 24 hours and used for experiments when they reached 
70%-90% confluency. Isolated RBCs were washed twice with cold HBSS and once with 
HBSS/A. RBCs were suspended to hematocrit 2.5% in HBSS/A. 10µL of RBCs suspension was 
used to measure the hemoglobin content as described above. Another 300µL of RBC suspension 
aliquot (hematocrit 2.5% in HBSS/A) was gently layered on confluent endothelial cells pre-
incubated with 150 µL of media containing different concentrations of (±)14(15)-EET (50651, 
Cayman Chemical, MI). The plate was incubated at 37° C for 40 min. An additional 83 µL of 
HBSS/A was gently added to create a slight convex meniscus over each well, and the plate was 
covered with an adhesive plastic film (89087-692, VWR, IL, USA). The plate was then inverted 
and allowed to sit for an additional 30 min at 37° C. With the plate maintained in the inverted 
position, the adhesive sheet was removed and the remaining fluid was removed by aspiration. 
200 µL 0.5% SDS was added to each well, followed by 5 hours incubation at room temperature. 
The amount of hemoglobin in each well was measured from the optical density (OD) as 
described above. Adherence was calculated as the percentage of OD of adhered hemoglobin/ 
(OD of total hemoglobin x dilution factor).
RBC adherence assay in flow condition
Freshly isolated red blood cells were diluted to 0.5 hematocrit in saline solution and passed at a 
fixed rate for 20 minutes over endothelial cells plated on a coverslip in recording and imaging 
chamber (ALA scientific instruments). The coverslip was then mounted over a glass slide and 
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the number of RBCs attached to endothelial cells was counted under light microscope at 10 
different places on coverslip.
Immunofluorescence
Isolated RBCs were washed 3 times with 1xPBS, blocked with 10% goat serum for 15 minutes at 
37o C, incubated with primary antibodies against human amylin (1:200, T-4157, Bachem-
Peninsula Laboratories) and Glycophorin A (1:100, sc-71159, Santa Cruz Biotechnology, TX, 
USA) for 15 min at 37o C, followed by incubation with anti-mouse IgG and anti-rabbit IgG 
secondary antibodies for 15 min at 37o C. Cells were hemolyzed in 1% saponin in PBS, 
centrifuged at 8000g for 5 min and the pellet was re-suspended in 1xPBS for microscopy. Images 
were obtained on a Nikon A1R confocal microscope (Nikon, NY, USA).
For hemoglobin staining, blood smears on glass slide were fixed in 
acetone/ethanol/methanol (6:2:2) for 20 minutes at RT. Smears were air-dried and re-hydrated in 
1xPBS for 5 minutes, rinsed briefly in distilled water, and incubated with pre warmed (37oC) 
trypsin solution (0.1% in calcium chloride 0.1% pH 7.8) for 15 minutes in humidity chamber. 
Next, smears were washed in PBS for 5 minutes with gentle agitation, rinsed in distilled water 
and air dried. Smears were then incubated at 37oC with primary antibodies against hemoglobin 
(1:100, ab92492, Abcam, MA, USA) and human amylin (1:100, SC-377530, Santa Cruz 
Biotech, TX, USA) in humidity chamber for 30-40 minutes. They were next washed, air-dried 
and covered with anti-mouse IgG and anti-rabbit IgG secondary antibodies for 20-30 minutes at 
37oC. After incubation smears were washed with PBS, rinsed in water, air dried and mounted in 
mounting media. Thin sections of paraffin embedded pancreatic tissues were co-stained with 
Thioflavin S and an anti-amylin antibody. 
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Enzyme-linked immunosorbent assay (ELISA)
ELISA assays for human amylin (EZHA-52K, Millipore, MA; EIA-AMY-5, Raybiotech, GA, 
USA), erythropoietin (EPO; 442807, Biolegend, CA, USA), hypoxia-inducible transcription 
factor 1α (HIF1-α; MBS764727, MyBioSource, CA, USA), hypoxia-inducible transcription 
factor 2α (HIF2-α; MBS2601406, MyBioSource), arginase 1 (MBS289817, MyBioSource), 
arginase 2 (MBS7216305, MyBioSource), von Hippel-Lindau (vHL; MBS288882, 
MyBioSource) and VCAM-1 (LS-F24285, LifeSpan BioSciences, Inc, WA, USA) were 
performed according to the manufacturer’s protocols..
Arginase activity assay
Arginase activity was measured in kidney homogenates using a colorimetric assay (MAK112, 
Sigma, MO, USA). To eliminate urine from kidney samples, 300µL of kidney homogenate were 
filtered through a 10kD spin column (88513, ThermoFisher, MA, USA) with centrifugation at 
15000g for 60 min, 4oC. Collected remnant was used for experiments. Assay was performed 
according to the manufacturer’s protocol. Briefly, filtered kidney samples were incubated with 
reaction substrate mix for 2 hours at 37o C. The stop solution was applied, followed by 
incubation at 37o C for 35 min. Absorbance reading was taken at 430 nm. Arginase activity was 
calculated based on manufacturer’s analysis instruction. 
Isolation of kidney capillaries 
Kidney capillaries were isolated by using the protocol used for the isolation of brain capillaries 
as describes previouslyS2. Briefly, kidneys were homogenized in ice cold cPBS and were mixed 
with 30% Ficoll solution by gently inverting tubes and then centrifuged 5800g for 20 minutes at 
4oC.  Pellets were re-suspended in ice cold cPBS with 1%BSA and were passed through the glass 
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beads column. Beads were agitated in cPBS with 1%PBS using 25mL pipette and solutions were 
taken equally in two 50mL tubes. Tubes were centrifuged and pellets were dissolved in 0.5 to 
1mL cPBS and used for experiment. 
Immunoblot
Western blot analysis was performed on plasma, WBC lysates, and RBC lysates from humans 
using a primary antibody against amylin (1:2,000, T-4157, Bachem-Peninsula Laboratories). 
Western blot analysis for VCAM-1 (1:1000, ab134047, Abcam) was done on kidney capillary 
lysates from WT and HIP rats
Immunohistochemistry
Immunohistochemical staining was performed on rat kidney slices using antibodies against 
amylin (1:200, SC-377530, Santa Cruz), collagen IV (1:1000, ab6586, Abcam), IBA-1(1:200, 
019-19741, Wako, VA, USA), and EDI (1:100, MCA341GA, Biorad, PA, USA). Biotinylated 
anti-mouse (1:400, BA2000, Vector lab, CA, USA), AP conjugated anti-mouse and anti-rabbit 
IgG (1:50, A3562, A3687, Sigma) were the secondary antibodies. The staining area for amylin 
was analyzed by ImageJ. The imaging area is 1280 x 1024 pixels; 1 pixel2 is 0.053 µm2 for 40X 
objective lens.
Transmission electron microscopy
Fresh red blood cells were fixed in 0.1M Sorensen’s phosphate buffer with 4% PFA and 0.2% 
glutaraldehyde for 1-2 hours. Cells were then washed in 0.1M Sorensen’s buffer and blocked in 
0.1% sodium borohydride for 15 minutes and incubated in AURION blocking solution 
(AURION blocking solution, 50-247-65, fisher scientific) for 60 minutes. Cells were washed 
with incubation buffer and incubated with primary antibody (anti-human amylin; T-4157; 
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Peninsula lab) for 2 hours at RT. Cells were rinsed with incubation buffer and incubated with 
secondary antibody (anti-Rabbit IgG-10nm Gold; ab27234, Abcam) overnight at 4 ºC. Cells 
were then washed in PBS and post-fixed in 2% glutaraldehyde for 2 hours. Cells were silver 
stained using Silver enhancement kit (ab170732, Abcam) and fixed in 0.5% OsO4 in 0.1M 
Sorensen’s buffer for 15 minutes. Cells were embedded in Epoxy resin and thin sections were 
prepared over nickel grid (T300-Ni, Electron microscopy science) for imaging in Transmission 
Electron Microscope (FEI Talos F200X, Thermo Scientific).
High resolution Stochastic Optical Reconstruction Microscopy (STORM)
Fresh red blood cells were stained using the same protocol as for immunofluorescence using 
primary antibodies (anti-human amylin; T-4157; Peninsula lab and anti-glycophorin A; sc-
71159Santacuz biotech) and secondary antibodies (rabbit IgG-atto 647 and mouse IgG-atto 488). 
Cells were kept in STORM imaging buffer {7µl GLOX (oxygen scavenger)+ 70µl of MEA 
(Cysteamine hydrochloride)+ 620µl of buffer B (Tris-HCL/NaCl)} during imaging on Nikon N-
SIM N-STORM (Nikon) microscope.
RBCs osmotic resistance test
The osmotic resistance of RBCs was assessed by measuring hemolysis at various concentrations 
of NaCl. Solutions with NaCl concentrations between 0 and 9g/L were obtained by mixing 
normal saline solution (containing 9g/L NaCl) with distilled water in various proportions. 285µl 
of each solution was placed in an Eppendorf tube. 4µl of RBC lysate was then added to tubes, 
mixed and incubated at room temperature for 30 min. The tubes were then centrifuged at 600 × g 
for 5 min. The supernatant was collected and the amount of hemoglobin released was detected by 
measuring the O.D. at 540 nm. For each sample, the % hemolysis at a given NaCl concentration 
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was calculated assuming that complete hemolysis occurs in distilled water. All samples were run 
in duplicate.
Oxygen dissociation curve
Fresh heparinized blood was oxygenated by blowing air on its surface in small vessels with 
swirling for a few seconds. 200µl of buffer (20mM phosphate in isotonic NaCl) was pipetted in a 
XF96 plate (Agilent Technologies, CA, USA) and 4µl of blood and 4µl of active yeast cell 
suspension were added to each well. The partial pressure of oxygen was then recorded at 
different time points in a Seahorse XF96 Extracellular Flux Analyzer (Agilent Technologies, 
CA, USA) until 100% oxygen consumption. Percentage saturation was then calculated and 
oxygen dissociation curve was plotted as described previouslyS6.
Reticulocyte count
For reticulocyte counting, 2-3 drops of filtered new methylene blue solution (New methylene 
blue 1g, sodium citrate 0.6g, sodium chloride 0.7g and distilled water 100ml) mixed with equal 
amount of blood and incubated at 37ºC for 15 minutes. After gentle mixing, thin smear of blood 
was prepared in glass slide and air dried.  Reticulocytes and RBCs were counted under a light 
microscope and the percentage of reticulocytes relative to the total number of RBCs was 
calculated.
Statistical analysis for animal data
Statistical differences between groups were determined using student’s t-test, one-way ANOVA 
or two-way ANOVA, as appropriate. Data are presented as mean ± standard error. Differences 
between groups were considered significant when P <0.05. All analyses were performed using 
GraphPad Prism 5.0 software.
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Full unedited gel for Figure S1
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